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Abstract 
The syndecans are the major family of transmembrane proteoglycans, usually bearing multiple 
heparan sulphate chains. They are present on virtually all nucleated cells of vertebrates, and are 
also present in invertebrates, indicative of a long evolutionary history. Genetic models in both 
vertebrates and invertebrates have shown that syndecans link to the actin cytoskeleton and can 
fine tune cell adhesion, migration, junction formation, polarity and differentiation.  Although often 
associated as co-receptors with other classes of receptors, e.g. integrins, growth factor and 
morphogen receptors, syndecans can nonetheless signal to the cytoplasm in discrete ways. 
Syndecan expression levels are upregulated in development, tissue repair and an array of human 
diseases, which has led to increased appreciation that they may be important in pathogenesis not 
only as diagnostic or prognostic agents, but also as potential targets. Here, their functions in 
development and inflammatory diseases are summarised, including their potential roles as 
conduits for viral pathogen entry into cells.  




Two small families of cell surface heparan sulphate proteoglycans (HSPGs) are present on nearly 
all cells of vertebrates. The transmembrane syndecans are type I membrane proteins with three or 
more glycosaminoglycan chains attached close to the N-terminus, i.e. distal to the cell surface (1). 
In contrast the glypicans are attached to the membrane through a glycosylphosphatidylinositol 
linkage and are therefore not transmembrane. They also have the potential for three or more 
heparan sulphate chains, but due to the globular nature of the core protein and a more C-terminal 
location (2), the chains are likely to be membrane proximal. The syndecans and glypicans together 
comprise the majority of cell surface HSPGs, though others may also be present, including a splice 
variant of CD44,  betaglycan and neuropilin-1, though heparan sulphate (HS) chains are not always 
present in these cases (3). While some experiments in invertebrates indicate partial redundancy 
between syndecans and glypicans (4), current evidence would suggest that this is not apparent in 
vertebrates. For example, of the six mammalian glypicans, deletion or mutation in three, 
glypicans-3, -4 and -6 give rise to developmental defects, each of which is distinct and argues for 
selectivity in glypican function and a lack of redundancy with syndecans (2,5).  
To date, there are no known mutations in syndecan core proteins that give rise to disease in man. 
However, several single nucleotide polymorphisms in syndecan genes have been reported to 
associate with disease, particularly connected to lipid metabolism. Two SNPs in SDC3 resulting in 
conservative amino acid changes in the core protein extracellular domain associate with obesity in 
a Korean population (6).  A non-coding region SNP in SDC4 associates with high triglyceride levels, 
decreased longevity, coronary artery disease and hypertension (7), while one SDC1 SNP in the 
3´UTR associates with increased likelihood of breast cancer in an Australian caucasian female 
population (8). The linkage to lipid metabolism has also been recorded in mice, where the 
syndecan-3 null is resistant to diet-induced obesity (9). Moreover, the single syndecan of 
Drosophila has been shown to regulate lipid and whole body energy metabolism (10). Increasingly, 
altered expression of syndecans in a variety of diseases of the vasculature, cancers and 
inflammation has stimulated research into their function. It is now clear that in some well-defined 
cases, e.g. myeloma, mis-expressed syndecan can be a driver to disease progression (11), while in 
others, syndecans are strong prognostic indicators, e.g. breast cancer (12,13). There is now much 
interest in syndecan functions in stem cells, which is reviewed here, along with summaries of 
syndecan core protein function, HS chain interactions and properties that indicate roles in 
development and inflammatory disease.  
Syndecan distributions 
 
In the nematode, Caenorhabditis elegans, the single syndecan is expressed at all stages, but 
declines with age (4,14). In adults, sdn-1 mRNA expression is detected throughout the nervous 
system, hypodermis, germline and intestine (14,15). SDN-1 protein expression is predominantly 
observed in the nervous system of adults, especially in the nerve ring (14). Lower levels of 
expression are also visible in the hypodermis and vulva (14). SDN-1 expression level is very low in 
adult animals and it may not be possible to observe expression using fluorescent reporters in all 
tissues. Similarly in Drosophila, syndecan expression declines with age and has a prominently 
neuronal distribution, in axons, synapses and neuromuscular junctions (16-18). A stage specific 
enrichment is observed in mesoderm during gastrulation and cardiac cells during germ band 
retraction (19). Proteomic analyses reveal the protein in heart and brain (20,21). 
 
In mammals, the distribution of syndecan-3 is reminiscent of invertebrate syndecan, with a 
strongly neuronal distribution (3,22). In addition, it is present in stem cells, as discussed below and 
has roles in musculoskeletal development and disease (23). Its closest relative, syndecan-1 is 
widespread in epithelia where it can be the dominant syndecan, for example in skin, cornea and 
liver (24-26). It is also present in some lymphocyte populations, and as with the other syndecans is 
expressed most strongly in embryonic tissues and declines in postnatal life (3). Experimental work 
has shown a linkage between syndecan-1 expression and maintenance of the epithelial 
phenotype, involving as yet unresolved pathways and cadherins (27). 
 
Syndecan-4 is almost ubiquitous and is present in most nucleated cell types, though often at low 
levels (3). Roles in the adhesion of mesenchymal cells to extracellular matrix have been 
demonstrated many times (1,28-30) and it was shown many years ago to be an early response 
gene sensitive to NF-kB activation and is therefore markedly upregulated in inflammatory disease 
(31-33). Its closest relative is syndecan-2, typically localised in mesenchymal cells and was 
originally known as fibroglycan (34). Of recent interest is that some carcinomas undergoing forms 
of epithelial-mesenchymal transition express syndecan-2 unlike the normal parental epithelium. 
This has prompted research into the possibility that it may be a target in such diseases (35). 
 
Murine syndecan knock-outs and relation to disease 
None of the knock-outs of a murine syndecan have a lethal or severe developmental consequence,  but 
give rise to subtle developmental defects and also impaired responses to tissue injury in post-natal 
life.  Even a double deletion of syndecan-1 and -4 shows no severe developmental defects, 
suggesting that redundancy between syndecans, at least through development, may be an 
important property (36). Data from studies on the epidermis show clear differentiation defects in 
the double knockout that are absent in corresponding single knockouts (36), supporting the 
hypothesis that syndecans can substitute for each other.  
Table 1 lists reports from all four syndecans emanating from deletion studies, but not including 
cancer models. A variety of diseases have been investigated, but looking for an overall theme, 
many reported disease models show alterations in the vascular system and inflammation. It then 
appears that while vascular development is mostly unaffected through embryogenesis, the 
absence of a syndecan impacts tissue repair with abnormal vascular responses, likely as a result of 
the involvement of the immune system. The presence of a closed vascular system in vertebrates, 
along with the evolution of a highly complex immune system seem to have provided new roles for 
syndecans beyond those seen in invertebrates. This is entirely compatible with two rounds of gene 
duplication at the invertebrate-vertebrate boundary that have given rise to four mammalian 
syndecan genes (48).  
 
Syndecan core protein signalling 
All syndecans possess a short cytoplasmic domain that is inconsistent with any intrinsic kinase or 
phosphatase activity (Fig.1). However, it has been known for more than 20 years that syndecans 
can both interact with the actin cytoskeleton and signal through binding of specific proteins. Many 
years ago we described the cytoplasmic domains as having three identifiable regions (49). The 
membrane-proximal C1 and membrane-distal C2 are highly conserved across syndecan types and 
species to the extent that invertebrate syndecan is recognisable by these two motifs. These highly 
conserved regions of syndecan cytoplasmic domains are implicated in trafficking. For example, 
syndecan-1 is by far the most abundant family member on the surface of hepatocytes where one 
of its roles is to internalise specific plasma lipoproteins that bind to the external heparan sulphate 
chains (25). The C1 region, thorough involvement of ERK, and subsequent phosphorylation by Src 
and binding of cortactin appears to promote endocytosis from membrane rafts (50). In fact, taken 
as a whole, the literature indicates uptake of syndecans by almost every conceivable route; 
clathrin-mediated uptake (51,52), macropinocytosis of syndecan-1 in pancreatic adenocarcinoma 
(53) while syndecan-2 interacts with caveolins (54). The reasons for this variety are unresolved, 
but may have much to do with the accessory receptors that accompany the syndecan. The C2 
domain of syndecans interacts with a number of PDZ domain proteins (55) such as syntenin. This 
has been implicated in the biogenesis of exosomes (20), a process also involving Src and the C1 
domain (56). Very recently, syndecan-4-syntenin-Alix complexes have been proposed as essential 
in targeting Escrt III to the membrane for completion of cytokinesis (57). While this may be one 
mechanism, syndecan-4 null cells are competent to complete mitosis.  
At first sight, major roles for syndecans, through cytoskeletal interactions in regulating adhesion 
and migration, seem unrelated to roles in lipoprotein uptake and other endocytic events, but 
there are connections. Integrin recycling, for example, involving uptake, redistribution and 
membrane insertion has been shown to involve syndecans (28,29), while it has long been thought 
that organelles such as focal adhesions resemble sites of frustrated endocytosis.  
The central V (variable) regions of syndecan cytoplasmic domains have presented considerable 
challenges. Very little is understood regarding those of syndecans-1, -2 and -3, although many 
potential interacting proteins have been identified (58). Each has a distinct amino acid sequence, 
while the vertebrate V regions are quite distinct from the larger V regions of invertebrate 
syndecans.  No signalling pathway involving the invertebrate V regions has been identified to date. 
Most is understood regarding syndecan-4 cytoplasmic domain and we were able to demonstrate a 
pathway involving protein kinase Cα (1,3,48). The cationic V region can interact with inositol 
phospholipid (PtdIns4,5P2) that induces a conformational change, imaged by NMR spectroscopy 
(59), which allows binding of protein kinase Cα in an active state. In turn there are several 
potential substrates that have downstream functions in the actin cytoskeleton (60,61) and calcium 
regulation. One PKC-dependent substrate is the stretch-activated TRPC7 channel that associates 
with syndecan-4 and α-actinin (36). Overall, it seems that syndecan-4 plays a key role in regulating 
the channel and when brought into play, there is a decrease in cytosolic calcium levels. Others 
have suggested the closely related TRPC6 can also be regulated by syndecan-4 (62). Consistent 
with this, molecular and genetic analysis suggests that syndecan-1 and -4 have roles in cell 
adhesion, junction formation and cell migration in part through TRPC channels. It provides a 
distinct adjunct to integrin-based functions with which the syndecans are often associated and 
suggests that syndecans can be sensors of mechanical stresses.  Genetic experiments in C. elegans 
suggest this property is ancient and conserved (36).  
The diverse functions of syndecans are exemplified by the large number of potential extra and -
intracellular binding partners, summarized recently (58). The four syndecans have in total 351 
potential binding partners. Out of these, approximately 100 are likely to interact with HS chains 
(58). The four syndecan core proteins share 18 binding proteins including themselves as they are 
capable of forming homo- and hetero-oligomers. They are largely cytoplasmic and include protein 
kinases (Fyn, Src), actin network organisers (cortactin syntenin-1, neurofibromin), α and β tubulin, 
the transport protein synbindin, and proteins involved in different signalling pathways (CASK, 
synectin, GIPC-1, TIAM1, the transmembrane integrin α6β4 and HS-binding FGF2. The 74 
syndecan-1-specific binding proteins are mainly related to integrin and growth factor/cytokine 
signalling pathways and interestingly, syndecan-1 is the only syndecan family member suggested 
to interact with fibrillar collagens I, III and V. There are also more reports of pathogens binding to 
syndecan-1 than other family members, but since it is also the most extensively studied member 
of this family, most likely our knowledge is far from complete. 25% of the 56 syndecan-2-specific 
binding partners are proteins associated with lysosomes while the 11 binding partners of 
syndecan-3 include molecules involved in cell communication and transduction, axon guidance 
and by interacting with the Sulf-1 and Sulf-2 sulphatases, has a regulatory role in post-export HS 
editing. 71% of syndecan-4-specific binding proteins are implicated in integrin signalling, the rest 
are extracellular or associated with exosomes with roles in cell communication (58). Another 
review from 2019 uses bioinformatics tools to predict binding partners of syndecans (63). 
Heparan sulphate and the ligand paradox 
The structure and synthesis of heparan sulphate (HS) have been well covered previously (64). A 
schematic shows the overall structure of the heparan and chondroitin glycosaminoglycans (Fig 1). 
A notable property of these polysaccharides is the presence of sulphate and uronic acid residues 
that impart strong anionic properties. Unsurprisingly therefore, many proteins with clusters of 
basic amino acids have the potential to interact with HS chains. In some cases, a very precise fine 
structure of HS in terms of sulphation is required for interaction, the best example being 
antithrombin III (64). For many other ligands, however, lower levels of specificity in HS fine 
structure apply (65,66). In the clinical setting, heparin and its ability to bind antithrombin III is of 
great importance. Heparin is a specialised form of HS with high levels of sulphation including a 
specific 3-O-sulphate moiety (64,67). It is initially synthesised as a proteoglycan, the core protein 
being serglycin. Subsequently, the heparin chains are cleaved to generate oligosaccharides. As well 
as its use as an antithrombotic agent it is used in research as a readily obtainable model 
glycosaminoglycan, and there is abundant literature where particular proteins are described as 
having heparin-binding domains. In most cells and tissues, however, HS of lower sulphation, 
attached to core proteins of the syndecans, glypicans and basement membrane proteoglycans are 
the sites of most physiologically relevant ligand interactions (65,68). An intriguing question, not 
fully answered is to what extent in vivo there is uniformity of, for example, skin keratinocyte 
syndecan-1 HS chains and how this changes through development, tissue repair and 
tumourigenesis. Whether fibroblast syndecan-4 HS chains are distinct from those of syndecan-2 or 
glypican in the same cell in vivo is unknown, but some HS-directed antibody studies certainly 
suggest that there are tissue and cell specific HS chains (69,70). The organisation of sulphated 
domains of glycosaminoglycan chains in vivo is far from random, but the extent of variance is 
unclear.  
Hundreds of proteins have been shown to bind heparin (and/or HS). Major families include 
chemokines, cytokines, extracellular matrix proteins and collagens, morphogens, growth factors, 
mediators of lipid metabolism and a variety of enzymes. In addition, as described below number of 
pathogens, most notably viruses bind to cell surface HS. Several bacteria have been described to 
utilise syndecans for infectivity, including Bacillus anthracis, B. cereus, Listeria monocytogenes, 
Pseudomonas aeruginosa and Streptococcus pneumoniae (71). In addition, much work has 
focussed on Plasmodium, the malarial parasite (72). 
With so many potential ligands, the question arises how protein interactions with HSPGs can 
generate specific information for cells and tissues? In many cases, further receptors are involved, 
with the frequent observation that ternary complexes of ligand, HSPG and other receptor are 
functional. Examples include fibroblast growth factor receptors, integrins, frizzled receptors, 
vascular endothelial growth factor receptors and Slit/Robo (1,28,30, 73,74 and see below). 
Nonetheless, syndecans are transmembrane and can signal in their own right. Therefore, it 
appears that ligands interacting with HS chains of syndecans impart a common set of signals, some 
at least influencing the actin cytoskeleton. This is consistent with data from developmental studies 
in invertebrates and lower vertebrates, knock-out and transgenic mice, and in vitro experiments 
that point to roles for syndecans in adhesion, migration and polarity. 
HS and fibroblast growth factors 
In their review, Matsuo and Kimura-Yoshida (75) suggest that the spatio-temporal distribution, 
sulphation pattern, and length of HS chains modulate the binding and signalling activation for 
different growth factors and their distribution during morphogenesis. In these processes, the cell 
surface HSPGs can function as co-receptors and endocytosis mediators.  
One of the earliest examples of cell surface HS requirement for growth factor activity involved the 
fibroblast growth factor family (75). An extensive literature has now developed over the past 30 
years (76-79). The extensively sulphated HS chains can promote the ternary complex formation 
with FGF (fibroblast growth factor) and its receptor FGFR (fibroblast growth factor receptor) 
leading to enhanced FGF signalling (80) while desulphation of HS downregulates FGF signalling 
activity (81,82). An important principle has emerged from studies of FGF2/FGFR and HS. A minimal 
HS pentasaccharide is required for binding FGF2 but this is not mitogenic. A longer (at least 
decamer) HS oligosaccharide is required that includes a 6-O-sulphated region binding to the FGFR. 
In this way a ternary complex of HS/FGF2/FGFR is stabilised for signalling and mitogenesis. FGF 
proteins can be stably co-localized with syndecan-1 (83) while in macrophages syndecan-2, 
selectively binds FGF2 in a form that trans-activates receptor-bearing BaF3 lymphoma cells 
transfected with human FGFR (34). In human metastatic melanoma cell lines, both CS and HS-
bearing proteoglycans were shown to be partners of bFGF-mediated proliferation (84,85). These 
interactions are not exclusive to cell surface proteoglycans since basement membrane perlecan 
also binds bFGF through its HS chains (86). Perlecan has been also described to form ternary 
complex with FGF18 and FGFR3 in a HS-dependent manner during cartilage development (87).  
Heparan sulphate: post-translational editing 
Heparan sulphate can be subject to two distinct types of modification once on the cell surface. Their effects 
are not limited to syndecans, but can extend to any cell surface heparan sulphate. The heparanase-1 
endoglycosidase enzyme (88) cleaves the chains into oligosaccharides, which if large enough can retain 
biological activity. Released oligosaccharides therefore can serve as competitors for the binding of growth 
factors and cytokines, for example. Moreover, heparanase-1 can promote signalling, and regulate 
transcriptional events, exosome formation and autophagy in promoting cell survival (89). Expression of 
heparanase is regulated and known to be increased in several different types of cancer (88,90).  
Heparanase inhibitors have been developed, some of which are in trials as cancer therapeutics (889,90). 
Less is known about a homologue, heparanase-2, though it has no enzymatic activity, and may be a 
heparanase inhibitor (91) 
There are also two mammalian sulphatases (Sulf1 and Sulf2) that selectively remove some 6-O-sulphates 
from heparan sulphate chains (92). This can have the effect of modifying the affinity of heparan sulphate 
for binding ligands and again there is evidence for upregulation, notably of Sulf2, in some types of cancer 
(93).  
HS and Wnt signalling 
The Wnt signalling pathway is one of the most conserved pathways in metazoans with important 
role during embryogenesis as well as in maintaining tissue homeostasis in adult organisms by 
promoting tissue renewal and reorganization (94). As with many morphogens and growth factors, 
Wnt signalling can also be subverted in disease. In a Wnt-1 model of mammary carcinoma in the 
mouse, syndecan-1 was shown to be essential (95). Wnt signalling has two main branches: the 
canonical Wnt/β-catenin and the non-canonical pathways that can be further divided into planar 
cell polarity and calcium pathways. The first evidence of involvement of GAG chains in Wnt 
signalling came in 1997 from Drosophila experiments and the involvement of glypicans and 
syndecans in Wnt signalling has been shown in many other model organisms (94,96). There are 
multiple points at which HS chains can be involved in Wnt signalling, going beyond the fact that 
Wnt ligands have heparin and HS-binding ability. In addition, evidence suggests that syndecans 
and glypicans at the cell surface can mediate Wnt signalling, but to what extent these are 
redundant pathways is not yet clear. In several instances, including Xenopus planar cell polarity 
processes, foregut formation and gastrulation, also muscle satellite cells, a functional complex of 
Fzd7 and syndecan-4 has been noted (97-100). 
Desulphation of HS by Sulf1 and Sulf2 6-O-endosulfatases promotes the binding of Wnt ligands to 
Fzd (Frizzled) receptors (101). Desulphation of HS on glypican-1 results in decreased affinity of 
Wnt-HS interactions with indirect facilitation of Wnt-Fzd complex formation (102). Glypican-3 
directly interacts with Wnt and Fzd through GAG chains (103). In hepatocellular carcinoma (HCC) 
cells and mouse models researchers identified the Wnt binding domain on glypican-3 as being a 
phenylalanine 41 residue in the hydrophobic groove in the N-lobe and both the core protein and 
HS chains can activate Wnt-β-catenin signalling (104). Syndecan-1’s HS chains promote cell 
proliferation by directly binding Wnt3a and activating paracrine Wnt-Fzd signalling in multiple 
myeloma (105). Moreover, Ren at al. (105) demonstrated that knock down of EXT1 (critical 
component of the polymerases in HS synthesis) mediated aberrant Wnt/β-catenin pathway 
activation in melanoma. In addition, the R-spondins can bind HS. These extracellular proteins 
through interaction with Lgr4-6 proteins lead to the suppression of Fzd ubiquitination by the 
closely related ZNRF3/RNF43 E3 ligases (106). However, recent data suggested that R-spondins 
may function in the absence of Lgr receptors, providing HSPGs were available (107). In at least two 
ways, therefore, HSPGs can mediate and amplify Wnt signalling.  
Glypican core proteins are unrelated to those of syndecans and undergo modifications that 
influence Wnt activity in ways not shared with syndecans. Notum was previously thought to act as 
a phospholipase cleaving Drosophila glypicans and thus regulating the distribution of Wnt (108). 
However, Vincent’s group in 2015 has shown that Notum requires glypicans, by virtue of 
interaction with HS chains, to supress Wnt signalling, but not by cleaving their GPI anchor (109). As 
revealed by kinetic and mass spectrometric analysis of human proteins, Notum acts as a 
carboxylesterase that removes the palmitoleate moiety of Wnts, which is important for receptor 
binding and in this case, therefore, glypican acts as a negative regulator of Wnt (109). Recent work 
also suggests that glypican-6 may inhibit Wnt5a in gut development (110). However, a very recent 
report illustrates the complexity of HSPG-Wnt interactions. A subset of glypicans (e.g. Dally-like in 
Drosophila and mammalian glypicans-4 and -6) may undergo a conformational change on binding 
Wnt that provides a hydrophobic pocket for the morphogen’s lipid moiety. In this way the 
morphogen can be dispersed and promote Wnt signalling (111).  
Hedgehog (Hh) proteins are a small family of morphogens that are important for many aspects of 
embryonic development and are implicated in several diseases (112,113). As with Wnts, they are 
lipoglycoproteins. Mammals express 3 Hh proteins: Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) 
and Desert Hedgehog (Dhh). The literature concerning syndecan interactions with Hh is sparse, in 
contrast to that with glypicans. It has been shown that syndecan-4 HS can bind Shh via a cationic 
motif (lysines 32-38) and lysine 178 in pancreatic ductal adenocarcinoma (PDAC) and pancreatic 
cancer (PANC1) cells (114).  Glypican-5 binds to both Hh and its receptor Ptc1 (Patched 1) via GAG 
chains (115), and perlecan can also function as a Shh coreceptor (116). 
Unlike HS chains, the biological function of syndecan chondroitin sulphate chains (CS) is less 
understood. It has been suggested that there is a cooperative role of CS and HS of syndecan-1 in 
laminin binding (117). In mouse mammary epithelial cells, the CS of syndecan-1 helps the faster 
binding and release of FGF2-FGFR1 complex from the HS chains (118,119). Syndecan-1’s CS chains 
also promote Slit signalling in axon and myotube guidance (120,121 ). The CS chains of syndecan-1 
are membrane-proximal and this region of the core protein is also commonly a target of 
metalloenzymes that can shed syndecans (122,123). A further untested possibility is that the CS 
chains shield this region from cleavage. It has been noted previously that clipping of HS chains by 
heparanase can render syndecans more susceptible to protease cleavage (124). 
Syndecan Shedding 
The membrane-proximal core proteins of the syndecans are exquisitely sensitive to a number of 
proteases. In vivo, the most likely candidates are matrix metalloproteinases (MMPs) and ADAMs (a 
disintegrin and metalloproteinase). Since metalloenzymes can be upregulated under conditions of 
inflammation, it is not surprising that there are many reports of syndecan shedding in tissue injury. 
This area has been reviewed recently (123). There can be several outcomes of these events. On 
one level, the shed proteoglycan, if it retains glycosaminoglycan chains, can act as a competitor of 
cell surface events (123). However, in some cases the shed proteoglycan may present bound 
ligands to other surface receptors, for example, with α4β1integrin and vascular endothelial growth 
factor receptor 2 (125). In addition, specific regions of the external core protein of syndecans have 
properties independent of glycans, and can inhibit syndecan-driven events (125, 126). The term 
“synstatin” has been coined to describe such inhibitory ectodomain polypeptides, notably of 
syndecan-1, and these have been shown to inhibit such processes as angiogenesis (125, 127). 
Cleavage of the ectodomain, leaves behind the syndecan transmembrane and cytoplasmic 
domains, the fate of which is largely unclear. There is a single report that this can be subject to y-
secretase cleavage, releasing the cytoplasmic domain into the cytosol (128). Another report 
suggests signalling through protein kinase Cγ to FAK and ERK to further increase MMP synthesis 
(129). However, information is sparse and in part this may be due to technical issues with tracking 
the fate of these small cytoplasmic domains. Syndecan-4 cytoplasmic domain has a distinct 
dimeric structure (59), easily disrupted by tag insertion. Tagging the C-terminus may result in 
preventing this C2 region from interacting with PDZ domain proteins such as syntenin or CASK (55-
57, 130), which could disrupt normal trafficking. However, since the cytoplasmic domains of 
syndecans link to the cytoskeleton and calcium channels, it would be interesting to know how 
shedding impacts these interactions.  
Syndecans in Invertebrate development  
Roles for HSPGs, including syndecans, in development were originally suggested over three 
decades ago (131). While syndecan knockout mouse models do not result in marked 
developmental defects, mutants in invertebrate models and zebrafish showed significant defects 
(14,132). However, all invertebrates of the Bilateria express only a single syndecan core protein 
(133,134). Therefore, its loss may be expected to have more impact on development. Zebrafish 
and other bony fishes do not express syndecan-1 and therefore have three core proteins, 
alongside the glypicans.  
 The core protein of invertebrate syndecans has limited sequence similarity with mammals, except 
in the cytoplasmic domain. The cytoplasmic domains of C. elegans and Drosophila syndecans have 
a high degree of sequence homology with mammalian syndecans, notably in the C1 and C2 
regions. Therefore, it is possible that the signalling through the cytoplasmic domain is conserved 
across species though very little is known about signalling through invertebrate cytoplasmic 
domains. For instance, C. elegans syndecan (SDN-1) cytoplasmic domain undergoes 
phosphorylation at a serine residue in the membrane proximal C1 region. This is similar to the 
previously shown phosphorylation of Ser179 in mammalian syndecan-4 (135) that may be 
important for receptor recycling. SDN-1 is expressed widely in C. elegans including nervous 
system, intestine, hypodermis and germline and controls egg laying and the development of 
neurons and germlines (14, 136-138). The expression of sdn-1 mRNA appears to be very high in 
embryos and moderate in early larval stages but low in young adults (139). In adults, the highest 
expression of sdn-1 is observed in the nerve ring, nerve cords and the vulva6.  Similarly, Drosophila 
syndecan (Sdc) is expressed from embryo through larval stages to adults, with the latter showing 
strong expression in nervous, circulatory, digestive and endocrine systems (140,141). While loss of 
sdn-1 is not associated with lethality in C. elegans, Sdc mutants showed partial lethality in 
Drosophila. 
Previous reports have shown that loss of the syndecan (SDN-1) in C. elegans has significant effects 
on development and behaviour of the organism. Early studies in C. elegans revealed roles for SDN-
1 in neuronal development. Hermaphrodite Specific Neuron (HSN), Anterior Lateral Microtubule 
(ALM), Anterior Ventral Microtubule (AVM), PVQ, and  Amphid interneurons (AIY) are a few 
examples of SDN-1 controlled neurons during development (14,137,) (Fig. 2). In addition to a 
single syndecan HSPG, C. elegans genome also encodes two glypicans (lon-2 and gpn-2) and one 
perlecan (unc-52) and several CS-bearing proteins (142). However, the HS-bearing status of UNC-
52 is debated. HSPGs acts redundantly during neuronal development (e.g. AIY neurons), at least in 
the case of SDN-1 and LON-2. However, triple mutants for sdn-1, lon-2 and unc-52 showed 
significantly increased developmental defects in multiple neurons compared to single mutants or 
sdn-1 and lon-2 double mutants. This suggested UNC-52 may have functions in independent 
pathways (138,143). The other glypican, GPN-1, does not appear to have any effect on neuronal 
development on its own. However, together with SDN-1 it appears to control ventral neuroblast 
migration through Kallmann syndrome protein (KAL-1) in a HS chain-dependent manner (144). 
The majority, if not all of the neuronal defects resulting from loss of SDN-1 are due to an impaired 
migration of the cell or cell type. The migration defects can be decreased or increased migration, 
or guidance defects (directionality)(14).  For instance, HSN cell bodies follow specific migration 
pattern and axons are extended in a stereotypic manner in wildtype worms (14,36, ). In the 
absence of syndecan, HSN cell bodies failed to migrate to their correct position and outgrowing 
axons were misguided (14,36). HSN migration appears to be a Wnt signalling-dependent process, 
where the wnt ligand EGL-20 plays a crucial role. It has been reported that egl-20 requires SDN-1 
to mediate HSN migration.  Similarly, anteriorly directed extension of PVQ neurons is often 
misguided in sdn-1 mutant worms (145,146). Consistent with data from mammalian cell systems, 
both HSN and PVQ defects in sdn-1 mutant worms were shown to involve dysregulated calcium 
metabolism in these neurons (36). It is also reported that loss of lon-2 in sdn-1 mutant can further 
enhance the defects in HSN development and axon branching, though any role for LON-2 in 
regulating calcium is unclear (147). Drosophila also exhibits neuronal anatomy defects in the 
absence of Sdc, the proteoglycan being required for the development of CNS in embryos by 
regulating the Slit family of secreted extracellular matrix proteins (18,148). Interestingly, the 
cytoplasmic domain of syndecan appears to be dispensable for syndecan controlled slit signalling 
(49). This is consistent with the findings that both slit and its receptor, robo exhibit binding to 
heparan sulphate that is essential for function (18,148,150). Moreover, it has been suggested that 
heparan sulphate deficiency, with impact on slit/robo signalling, may be associated with the 
autistic phenotype in humans (151). Finally, Sdc along with glypican appears to control 
neuromuscular junction development in Drosophila through a tyrosine phosphatase mediated 
process (19,152). 
Syndecans and Vertebrate Neuronal Development 
Studies in vertebrate models have revealed a similar role for syndecans in neuronal development. 
The roles for vertebrate syndecans in nervous system appear to be fulfilled mostly, but not 
exclusively, by syndecan-3.  The syndecan-3 knockout mouse nervous system develops normally, 
except for subtle defects. For example, there was delayed radial neuronal migration in the cortex, 
which was rectified within ten days after birth (22). In order to control neuronal migration in the 
mouse brain, syndecan-3 appears to signal with Src kinases, cortactin and EGFR25. Vertebrate 
success is, in part, due to the origination and plasticity of neural crest. In zebrafish, the migration 
of neural crest cells is controlled (153). Similar to the single syndecan in C. elegans, syndecan-4 is 
expressed throughout the early embryonic stages of zebrafish (154). Syndecan-4 knockdown in 
zebrafish resulted in excessive proliferation of neural cells and aberrant branching of axons. 
Impaired axon branching indicates defective migration of cells during development, which is 
therefore similar to invertebrate models (154). These studies collectively show that both 
vertebrate and invertebrate syndecans are required for neuronal development. However, the loss 
of function mutants exhibit less severe phenotype in vertebrates, particularly mammals, perhaps 
due to the redundancy between syndecan isoforms.     
Nematode germline development  
In addition to neurons, germline development in C. elegans is influenced by SDN-1 (155). C. 
elegans germline development requires the controlled migration of a special cell called the distal 
tip cell (DTC), which later acts as a stem cell niche for germline stem cells in adult worms. DTCs in 
embryos have positional specificity along with somatic gonad and migrate to the required position 
during larval growth (larval stage L1 to L4) to complete germline development (Fig. 2). During this 
process, signals from DTC promotes the proliferation of germline cells (156). It has been reported 
that RNAi targeting sdn-1 results in defective migration of the DTC (155). It is possible that this 
could have resulted in a defective germline, supported by the finding that sdn-1 mutant 
hermaphrodite worms showed a significant reduction in the number of offspring (121). While 
glypican mutants in C. elegans did not have any reported germline defects, they also produced a 
lower number of offspring. Similarly, one mutation in Drosophila Sdc resulted in semi-fertile 
females suggesting possible germline defects (132). Currently, no data is available on the effect of 
syndecan loss on the mammalian germline, but single knockout mice are fertile and can 
reproduce. 
 
Syndecans in stem cells 
Heparan sulphate proteoglycans are expressed ubiquitously in stem cell niches and play important 
role in controlling stem cell fate. While significant information about the role of syndecans during 
development came from invertebrate models, the role of syndecans in stem cells have been 
elucidated mostly in vertebrates. Similar to several other signalling pathways, syndecan mediated 
signalling in stem cells can be initiated by HS chain interactions with ligands. Among the plethora 
of pathways controlling stem cell development, syndecans appear to regulate Wnt, BMP and 
Notch signalling (157,158). It has been well established that syndecans are involved in tissue 
regeneration, wound healing and cancer progression (3,159). The cells under these conditions 
have remarkable similarities to stem cells where they proliferate quickly and undergo 
morphological and transcriptional changes (160-162). Therefore it is likely that syndecans control 
the same signalling in stem cells as they do during tissue regeneration and cancer development.  
 
Initial reports documented the expression of syndecans in mouse bone marrow cells, suggesting a 
possible role for syndecans in hematopoietic stem cells (163). However, syndecan functions in 
stem cells were elucidated in detail using muscle and neuronal stem cell models. The resident 
population of stem cells in muscles, the satellite cells, must be activated in response to injury in 
order to initiate muscle regeneration (164). Syndecan-3 and syndecan-4 are expressed in the 
satellite stem cell niche whereas syndecan-1 is absent in postnatal muscles (165,166). In general, 
the expression of HSPGs is down-regulated during satellite stem cell activation. This suggests that 
HSPGs are required for maintaining satellite cell quiescence (157,165). However, syndecan-4 is an 
exception, where it is upregulated in active satellite cells. It appears that syndecan-3 and 
syndecan-4 are essential for muscle regeneration and perform distinct functions in satellite cells. 
Syndecan-4 knockout satellite cells failed to activate and resulted in an impaired regeneration of 
muscles after chemically induced muscle injury (165,167). On the other hand, syndecan-3 null 
satellite cells exhibited abrupt differentiation post injury (168).  Notch signalling was identified to 
be the key pathway controlled by syndecan-3 during muscle regeneration (157).  
 
In differentiated rat neuronal stem cells, syndecan-3 expression is upregulated when 
differentiation is induced by retinoic acid (169). This indicated a possible role for syndecan-3 in 
neural stem cell differentiation. More recent data suggest that syndecan-1 is expressed highly in 
neural progenitor cells and knockdown of syndecan-1 results in reduced neural progenitor cell 
proliferation during cortical neurogenesis. Canonical Wnt signalling is a key pathway that controls 
cortical neurogenesis. The significant reduction in Wnt signalling in response to syndecan-1 
silencing was identified as the reason for reduced neural progenitor cell proliferation (158). Both 
muscle and neuronal stem cell models associated the expression of syndecans with proliferation. 
Accumulated data suggests that syndecans function during stem cell development at least through 
BMP, Wnt and Notch, all of which bind heparan sulphate. However, to elucidate the breadth of 
syndecan-mediated signalling in stem cells and their use as a marker for a particular stem cell 
population will require further study.  
 
Syndecans in Inflammation and Tissue Repair.  
HSPGs and the endothelial glycocalyx 
A defining feature of the endothelium is the luminal glycocalyx, which is a complex assemblage of 
sugars decorating the surface of the endothelium. The glycocalyx modulates vascular tone and 
permeability, as well as mediating inflammatory events. A major proportion of the sugar content 
of the glycocalyx is HS and despite the existence of several model systems in which the HS 
polymerase enzymes EXT1 and EXT2 are deleted there is limited information as to the impact this 
has on glycocalyx structure and function. Studies would suggest that they, and by extension HS, 
are important for maintaining both endothelial cell homeostasis and glycocalyx repair after insult 
(170,171).  The production of heparanase by leukocytes has attracted much attention based on 
the premise that glycocalyx degradation is a necessary step for efficient leukocyte transmigration. 
However, neutrophil and effector lymphocytes do not require this enzyme or indeed HS for 
efficient traversal of the endothelium, whereas there does appear to be some requirement for this 
enzyme in monocyte and macrophage transmigration (172-174). 
The principal HSPGs found on the luminal surface of ECs are the transmembrane syndecans-1, -2, 
and -4, and membrane-bound glypican-1 (175,176) in addition to several secreted HSPGs and a 
range of other glycoproteins. Loss of syndecan-1 results in a thinner glycocalyx (177), although the 
impact of the other HSPGs on this parameter has yet to be established. Numerous studies have 
identified shed syndecan-1 as a marker of both endothelial dysfunction and glycocalyx 
degradation, an example being ischemia reperfusion injury (178). Blockade of syndecan-1 
shedding led to a less inflammatory phenotype in a model of ulcerative colitis (179). Although 
other HSPGs are also shed under these circumstances, they are not regarded as robust biomarkers 
for EC dysfunction.  
HSPGs and Leukocytes 
Genetic deletion of syndecan family members results in phenotypes which mostly become 
apparent when these animals are challenged. There are many studies in which syndecan null 
animals have been tested in disease models where there is a significant inflammatory component. 
Despite this relatively little is known about the impact of syndecan deletion on factors such as 
leukocyte subset numbers, or indeed the extent of syndecan expression on different leukocyte cell 
types.  
An essential early process in wound healing is the initiation of clotting, which is primarily driven by 
platelets. Syndecan-4 is the only HSPG to be identified on these cells and its loss either by 
shedding or pharmacological blockade led to enhanced clotting responses primarily due to that 
fact it bound antithrombin (180). Neutrophils are the most abundant white blood cell and are 
recruited first to sites of inflammation, and there is evidence that they express both SDC1 and 
SDC4, albeit at low levels (181,182). Monocytes and macrophages express all 4 family members, 
although the situation is complex (183-185). Human monocytes can be differentiated into either 
macrophages or immature and mature dendritic cells. Syndecan-2, -3 and -4 mRNA can be 
detected at all stages of this differentiation process, however SDC1 mRNA is only apparent in 
immature dendritic cells (DC). This study also reported the complete absence of glypican-6 at all 
differentiation stages in contrast to glypican-4 which was evident in all. Glypican 5 appears in DCs 
at all stages, but not monocytes or macrophages, while glypican-1 was absent only from 
monocytes (186). A number of other studies confirmed the presence of all 4 syndecans on DCs by 
flow cytometry (187-189). This expression data raises the possibility that at least in the context of 
monocytes, macrophages and DCs there is likely to be multiple GAG bearing molecules on the cell 
surface, conceivably bearing GAG chains with distinct, core protein-specified properties. The 
situation is further complicated by the fact that syndecan expression is modulated by 
inflammatory stimuli and these same stimuli can promote syndecan ectodomain shedding. Innate 
lymphoid cells such as B and T cells also express syndecans. In both syndecan-1 and syndecan-4 
null animals elevated levels of NKT cells are observed (190). In syndecan-4 null mice this is linked 
with the absence of N-sulphation and appears protective in a Lewis lung carcinoma model (189). 
Absence of syndecan-1 correlates with an increased inflammatory response in models of psoriasis 
and this is linked to the elevated levels of a subset non-SDC1 expressing ƴδ T cells (191). Syndecan-
1 expression is associated with a number of B cell populations specifically terminally differentiated 
antibody secreting cells and is associated with enhanced pro-survival signals (192). This strong 
expression has also led to considerable interest in SDC1’s role in multiple myeloma. Mast cells also 
express syndecan-4 where it regulates extracellular heparanase uptake (193,194) and eosinophil 
migration is affected by absence of syndecan-4 (195). A summary of the differences in HSPG 
expression on leukocyte subsets is shown in Figure 3. 
HSPGs and Leukocyte extravasation. 
The extravasation of leukocytes from the circulation in response to inflammatory stimuli is a 
tightly regulated process involving multiple steps. These include the initial capture of circulating 
leukocytes by the endothelium, followed by a rolling phase, eventual arrest and finally 
extravasation through the endothelium (196). All of these events involve processes in which the 
HSPGs have been associated, in particular the syndecans. However, while some studies point to a 
role for syndecans in this process in various models of inflammation (23,90,122,197), a detailed 
analysis of the roles of syndecans and glypicans in the leukocyte adhesion cascade have yet to be 
undertaken. This may in part be due to the unsuccessful clinical trials of heparan sulphate 
analogues as anti-inflammatory agents. However, both leukocytes of all types and the 
endothelium all express at least one HSPG so this avenue of research might well be worth 
exploring.  
HSPGs and angiogenesis 
Angiogenesis, the formation of new blood vessels from existing vasculature is distinct from 
vasculogenesis in which new blood vessels emerge from endothelial stem cell precursors. It is an 
essential developmental process in animals with a closed vascular system and is also essential for 
physiological wound healing. Dysregulated angiogenesis in which the process is either upregulated 
or down regulated is a feature of numerous pathologies and as such has been a target for 
therapeutic intervention. In both development and disease, angiogenesis is regulated by both pro- 
and anti-angiogenic growth factors, the prime example being vascular endothelial growth factor A 
(VEGFA). There is considerable evidence that the majority of these factors can bind to HS and that 
their activity can be modulated by this interaction. Given this, it is surprising that there are few 
reports of roles for glypicans in this process with the majority of studies focusing on the 
syndecans. 
However, the proposed roles for syndecans in angiogenesis present a complex picture with 
contrasting roles for each family member (Fig 4). Despite SDC1 null animals developing a normal 
vasculature, roles for SDC1 in regulating pro-angiogenic signalling complexes have been identified. 
Specifically, interactions between integrins, IGFR2, VEGFR2 and VE-cadherin and SDC1 have been 
characterised and strategies which disrupt these complexes leads to an inhibition of angiogenesis 
(198-200). Syndecan-2 has been identified as having a role in branching angiogenesis during 
zebrafish embryonic development and a subtle defect is also observed in endothelial specific SDC2 
knockout mice (40,201). However, syndecan-2 in its shed form is a potent inhibitor of this process 
owing to an inhibitory amino acid sequence in its extracellular core protein (202). Far less is 
understood regarding syndecan-3, perhaps because its expression has been intimately associated 
with cells of a neuronal lineage and the musculoskeletal system. However several studies have 
identified it as being expressed on endothelium from various vascular beds both in vivo and in 
vitro (203,204). In common with syndecan-1 and 2, regulatory sequences contained within the 
core protein of syndecan-3 can inhibit EC migration and hence angiogenesis (205). However a 
contrasting role has also been reported whereby thrombin cleaved fragments of the syndecan-3 
ectodomain can promote vascular permeability possibly in concert with similar fragments from 
syndecan-4 (206). 
Perhaps the greatest complexity is in understanding the role of syndecan-4 in angiogenesis, 
particularly as to whether it has a role in the VEGFA/VEGFR2 signalling axis. Despite syndecan-4 
null mice developing normally there is evidence that syndecan-4 has a role in angiogenesis. For 
example, impaired wound healing in the knockout mouse is in part associated with defects in 
granulation tissue formation (42). Knockdown of syndecan-4 in cultured ECs leads to a reduction in 
VEGFR2 signalling in response to VEGFA and this is associated with a reduction in angiogenesis 
related processes such as EC migration (207).  However, in vivo studies using comparing a global 
syndecan-4 knockout mouse with an endothelial cell specific syndecan-2 knock out mouse suggest 
that syndecan-4 has no role in VEGFA signalling and it is in fact syndecan-2 which is responsible, 
particularly during development. This difference in function is related to differences in HS 
sulphation between the two, with syndecan-2 able to bind VEGFA more effectively due to 
enhanced levels of 6-O-sulphation (39). In contrast, during lymphangiogenesis syndecan-4 
mediates facilitates the interaction between VEGFC and VEGFR3 during both development and in 
pathological scenarios (208,209). Angiogenesis is also promoted by FGF-2 and there are a number 
of studies which indicate a pro-angiogenic role for syndecan-4 in FGF signalling (210-212). 
HSPGs in inflammatory Disease - Rheumatoid Arthritis 
A number of HSPGs have been identified in various cell types from the inflamed joints of RA 
patients. Immunohistochemical analysis revealed syndecan-1 expression on infiltrated immune 
cells in synovia of RA patients and syndecan-2 and -3 were evident on endothelial cells as was 
glypican-4. Syndecan-2 was also evident on mural cells, and syndecan-3 on macrophages (213). 
Despite this, studies investigating the roles syndecan-1 and -2 in RA are few, and this is also true of 
glypican-4. Syndecan-2 is associated with bone development but does not appear to have a 
pathological role in arthritic disease (214). Syndecan-4 expression was notably absent from the 
study described above, however later work revealed syndecan-4 has essential roles in RA 
pathology. For example, fibroblast like synoviocytes from RA patients have increased expression of 
syndecan-4 and showed that ablation of syndecan-4 reduced production of nitric oxide and 
reactive oxygen species, as well as production of IL-1β, IL-6 and TNF-α (215). Syndecan-4 null 
animals are protected in models of arthritis and disruption of an interaction between syndecan-4 
and the protein tyrosine phosphatase receptor PTPRσ on fibroblast like synoviocytes is associated 
with more severe disease progression in mouse models (216). During the pathogenesis of RA 
significant degradation of cartilage occurs and this is intimately associated with matrix 
metalloproteinases such as ADAMTS5. In models of osteoarthritis syndecan-4 has been shown to 
regulate ADAMTS5 activity via interactions with its HS chains and also via transcriptional 
regulation of MMP3 (43). The breach of immune tolerance in RA is also a critical step in the early 
onset of the disease. Syndecan-4 null animals are resistant to collagen induced arthritis which is T 
and B cell dependent and this correlated with reduced chemotactic migration in syndecan-4 
deficient B cells (217). 
In common with syndecan-4, syndecan-3 null mice are protected in models of RA and this is 
associated with a reduced infiltration of neutrophils into inflamed joints (40). Administration of a 
soluble form of syndecan-3 leads to more beneficial outcomes in both antigen induced and 
collagen induced arthritis and again this is associated with inhibition of leukocyte migration (218). 
These phenotypes are likely to be linked to the chemokine binding properties of syndecan-3, 
notably to CCL2, CCL7 and CXCL8 (218,219). 
HSPGs in Fibrosis. 
An essential part of normal wound healing is the production of ECM molecules for the restoration 
of the structural integrity of injured tissues. In circumstances such as chronic inflammation or 
repeated tissue injury excessive production of ECM molecules by fibroblasts can occur, leading to 
scarring and significant interference with an organ’s function. ECM production (e.g. collagens and 
GAGs) is predominantly driven by the pro-fibrotic TGF-β family of growth factors, of which there 
are 3 isoforms in mammals. TGF-β is secreted predominantly by macrophages in response to 
inflammatory stimuli and is produced in complex with LTBP (latent TGF-β binding protein) and LAP 
(latency associated peptide). This complex resides in the ECM and in this form TGF-β is not active, 
it is only when activation either by the action of proteases (e.g. plasmin), physiological changes 
such as pH or exposure to ROS, inhibition of complex formation by molecules such as 
thrombospondin-1 or by mechanical disruption through the action of αV integrins (220,221) There 
are three TGF-β receptors TGFBR1 and 2 transduce signals upon engagement with TGF-β isoforms, 
whereas TGFBR3 (betaglycan) acts as a sink sequestering the growth factor via interactions with its 
GAG chains (222).  
Of the HSPGs syndecan-2 and-4 have the most significant roles in fibrotic disease. Given their roles 
in focal adhesion formation, which are the sites of matrix deposition this is not unsurprising. 
Syndecan-2 has been shown to bind TGF-β and is upregulated in fibrotic tissue and in response to 
pro-fibrotic stimuli (223,224). Mice over expressing syndecan-2 show abrogated radiation induced 
lung fibrosis and this is linked to its interaction with the protein tyrosine phosphatase receptor 
CD148 (225,226). Syndecan-4 appears to have a protective role in fibrotic disease models since in 
its absence, outcomes tend to be worse. This has been linked to a number of factors including 
syndecan-4 being involved in the abrogation of TGF-β signalling (45) and an interaction with 
CXCL10 in lung fibrosis (227). In models of kidney fibrosis, loss of syndecan-4 resulted in a more 
severe phenotype indicating a more protective role associated with reduced activation of the 
collagen crosslinking enzyme transglutaminase-2 (228).  
Cell Surface Proteoglycans in Viral Interactions  
The polysaccharides of proteoglycans are the most anionic molecules located at cell surfaces by 
virtue of their sulphate and uronic acid content. A number of different pathogens utilise these 
polymers in ionic interactions that locate them to the cell surface, where they may engage with 
other receptors to gain entry into cells. Additionally, syndecans are known to be effective vehicles 
for endocytosis (28,29,56). Over the past 20 years it has become clear that many different types of 
virus can interact with heparan sulphate, and in some cases these interactions are essential for 
internalisation and pathogenesis that often includes inflammation. A recent in-depth review has 
summarised the data for over 50 different viruses (229). However, this review also makes clear 
that not all have been proven to apply to natural isolates. Examples where this has been 
demonstrated include Herpes simplex virus, Dengue virus, Echoviruses 5 and 6 and North 
American eastern equine encephalitis virus. Many others have shown HSPG dependence based on 
laboratory strains, or from adaption to cell culture conditions. Some, such as Zika virus and 
respiratory syncytial virus remain unresolved and require further evaluation.  
Much early work focussed on Herpes simplex virus (HSV), a double-stranded DNA virus and both 
HSV-1 and -2 attach to the cell surface in a HS-dependent manner. Two viral proteins gB and gC 
interact with HSPGs that allows translocation on epithelial cells to sites where the main receptors 
(nectin-1 and -2) and a protein (HVEA) of the TNF-α family can interact with the viral protein gD 
(230,231). Bacsa et al. (232) showed that downregulation of both syndecan-1 and sydecan-2 
inhibited HSV-1 entry into HeLa cells. Moreover a form of heparan sulphate containing 3-O-
sulphate residues was found to facilitate gD-mediated internalisation (230). This suggests that a 
ternary complex of specifically modified HS chains of a syndecan, gD protein and secondary cell 
surface receptors are responsible for internalisation. 
It is similarly clear from several studies employing heparan sulphate deficient cell lines, 
heparinases or chlorate to suppress sulphation (233), that the four Dengue virus serotypes require 
interaction with HSPGs at the cell surface. These primary interactions are followed by interactions 
with known entry proteins, such as DC-SIGN in dendritic cells and the mannose receptor in 
macrophages (234). The Dengue virus, an enveloped, single stranded RNA (ssRNA+) virus is a 
widespread pathogen, transmitted by Aedes mosquitoes, which can lead to haemorrhagic fever 
and shock syndrome that are potentially lethal.  
A third example is that many strains of the human papilloma virus (HPV) bind to cell surface 
HSPGs. These small non-enveloped dsDNA viruses can infect a range of epithelia with some 
strains, such as HPV16, being oncogenic and a cause of cervical carcinoma. This strain has 
therefore been well studied (229). Syndecan-1 on keratinocytes has been implicated as an initial 
binding site for these viruses (235), and two lysine residues in the capsid protein L1 have been 
earmarked as critical (236). Resulting from HSPG interactions, the HPV capsid undergoes 
conformational alterations that require cyclophilin B and cleavage of the L2 capsid protein. As a 
result, affinity for HSPGs is reduced and secondary receptors, presumably invoking endocytosis 
become involved. These may include epidermal growth factor receptor (EGFR), integrin α6 and 
tetraspanins (237).  
In all these cases, the use of highly anionic competitors, such as heparin and carageenans can be 
shown in vitro and sometimes in vivo to reduce pathogenicity (238). However, this type of agent 
has not been translated into successful prevention or treatment, and trials in the case of human 
immunodeficiency virus (HIV) were not successful (229).  
The potential use of competitors including heparin and fucoidans has surfaced again with respect 
to the current SARS-Cov-2 pandemic. This virus belongs to the coronavirus family, of which there 
are three major classes based on serological and other criteria (229). They are enveloped single 
strand RNA (ssRNA+) viruses. Previously, the ability of coronavirus to interact with heparan 
sulphate was shown after adaptation to culture (229,239). An example is the human OC43 virus 
where a mutation in a basic furin cleavage site of the spike protein preserved a heparan sulphate-
binding motif that became obligatory for infectivity (239). The current SAR-Cov-2 virus has rapidly 
been shown to possess a heparin-binding site in the spike 1 protein and that sulphated 
polysaccharides such as heparin and fucoidans inhibited viral entry in vitro (240). Heparan 
sulphate, with a lower sulphation level than heparin, was, however, ineffective (240). In further 
preliminary work, not currently peer-reviewed, both heparin and commercial low molecular 
weight heparin derivative, Enoxaparin were effective inhibitors (241). Other preliminary work 
suggested that HS octasaccharides could bind the SARS-Cov-2 spike protein, but these were highly 
sulphated, comprising trisulphated disaccharides (242). Intriguingly, a further recent report has 
suggested that cell surface HSPG was essential for infectivity and that spike protein binding to 
heparan sulphate and angiotensin converting enzyme 2 (ACE2) were codependent (243). In these 
studies, heparinases or the use of heparin, non-anticoagulant heparin and lung-derived heparan 
sulphate could block spike binding and infection (243).  Clearly these studies have a long way to 
go, but whether syndecans and/or glypicans are essential for SARS-Cov-2 infection is unknown 
currently. However, two recent reports indicate that neuropilin-1 and -2 can facilitate SAR-Cov-2 
entry and infection (244,245). Neuropilin-1 can possess a HS chain, but whether that is required is 
not yet established. It will be interesting to ascertain whether there are alterations in HS fine 
structure or abundance that contribute to the known increased susceptibility of older patients to 
severe lung disease.  
 
Concluding Remarks 
Since the first cDNA cloning of syndecan-1 in 1989 (246), some 4000 publications on these 
proteoglycans have appeared. They are now implicated in many developmental and disease 
processes and for some such as breast cancer, their presence and distribution can be prognostic 
(12,13). In the case of knock-out mice, none so far has proved to have serious or lethal 
repercussions. In lower vertebrates such as zebrafish possessing 3 syndecans and invertebrates 
that express one syndecan, developmental defects in mutants are more pronounced. Redundancy 
across syndecans has only occasionally been clearly demonstrated, but it is apparent that some 
morphogens and growth factors can functionally bind HS on either syndecans or glypicans. 
Redundancy between syndecans and glypicans in mammals would appear to be minimal, but a key 
question that remains is core protein specificity in terms of HS fine structure in vivo and its 
potential impact on protein ligand binding and function. 
Of the cell surface proteoglycans, only syndecans appear to work alongside integrins in regulating 
cell-extracellular matrix interactions, adhesion and cytoskeletal organisation. Analysis in C. elegans 
and Drosophila points to cell guidance mechanisms and polarity regulation as ancient syndecan 
functions that can also be demonstrated in mammals. Alongside gene duplications at the 
invertebrate- vertebrate boundary, additional properties have been acquired in parallel with the 
acquisition of closed vascular system, extensive skeletal tissues and complex immune systems. 
Signalling through the V regions of syndecans is still largely unknown, but since invertebrate and 
mammalian syndecans may regulate stretch-activated calcium channels, this may be a common 
signalling output impacting the actin cytoskeleton. An important component of the syndecan 
repertoire is endocytosis, shown to be a key component of lipoprotein uptake in the liver (25) and 
also in redistribution of the receptors with which they associate (28). There is also much to learn 
regarding syndecan shedding, known to be enhanced in conditions of stress, such as inflammation 
and diseases where sheddases are upregulated. This may well limit the ability of HS-binding 
ligands to effect signalling, through competition, but our knowledge is incomplete and may be 
intrinsic to the progression of a number of diseases. Certainly, loss of endothelial glycocalyx 
involves shedding of syndecans into the circulation, and broadly speaking shed syndecan-1 is 
accepted as a marker of endothelial dysfunction in sepsis and trauma. 
It has long been suspected that HS chains can concentrate ligands in the pericellular environment 
where they may interact with specific receptors. However, this is surely an over-simplification and 
does not explain why mammals express 10 distinct syndecan and glypican core proteins. 
Syndecans are transmembrane with linkage to the actin cytoskeleton, a repeated observation. 
Moreover, this is not simply a mechanism to locate syndecans at the cell surface; syndecan 
signalling impacts the cytoskeleton, and therefore junctions, migration and pathfinding. Given 
increasing evidence for roles in development and diseases, including some cancers, 
musculoskeletal, and cardiovascular diseases, their long evolutionary history and widespread 
tissue expression, it is clear that syndecans continue to deserve scrutiny for several distinct 
reasons, not least the possibility that they can be diagnostic, prognostic or even targets (e.g. 
syndecan-1 in myeloma;247) in specific diseases. 
 
References 
1. Mitsou I, Multhaupt HAB, Couchman JR. 2017. Proteoglycans, ion channels and cell-matrix 
adhesion. Biochem J. 474, 1965-1979. (doi: 10.1042/BCJ20160747). 
2. Li N, Gao W, Zhang YF, Ho M. 2018. Glypicans as cancer therapeutic targets. Trends Cancer 
4(11), 741-754. (doi:10.1016/j.trecan.2018.09.004). 
3. Couchman JR. 2010. Transmembrane signalling proteoglycans. Ann Rev Cell Dev Biol. 
26:89-114. (doi: 10.1146/annurev-cellbio-100109-104126).  
4. Saied-Santiago K, Townley RA, Attonito JD, da Cunha DS, Díaz-Balzac CA, Tecle E, Bülow HE. 
2017. Coordination of heparan sulfate proteoglycans with Wnt signaling to control cellular 
migrations and positioning in Caenorhabditis elegans. Genetics 206, 1951-1967. (doi: 
10.1534/genetics.116.198739). 
5. Amor DJ, Stephenson SEM, Mustapha M, Mensah MA, Ockeloen CW, Lee WS, Tankard RM, 
Phelan DG, Shinawi M, de Brouwer APM, et al. 2019. Pathogenic variants in GPC4 Cause Keipert 
Syndrome. Am J Hum Genet. 104, 914-924. (doi:10.1016/j.ajhg.2019.02.026). 
6. Ha E, Kim MJ, Choi BK, Rho JJ, Oh DJ, Rho TH, Kim KH, Lee HJ, Shin DH, Yim SV et al. 2006. 
Positive association of obesity with single nucleotide polymorphisms of syndecan 3 in the Korean 
population. J Clin Endocrinol Metab. 91:5095-9. (doi: 10.1210/jc.2005-2086).  
7. Kunnas T, Nikkari ST. 2014. Contribution of syndecan-4 genetic variants to hypertension, 
the TAMRISK study. BMC Res Notes. 19;7:815. (doi: 10.1186/1756-0500-7-815). 
8. Okolicsanyi RK, Buffiere A, Jacinto JM, Chacon-Cortes D, Chambers SK, Youl PH, Haupt LM, 
Griffiths LR. 2015. Association of heparan sulfate proteoglycans SDC1 and SDC4 polymorphisms 
with breast cancer in an Australian Caucasian population. Tumour Biol. 36:1731-8. (doi: 
10.1007/s13277-014-2774-3). 
9. Strader AD, Reizes O, Woods SC, Benoit SC, Seeley RJ. 2004. Mice lacking the syndecan-3 
gene are resistant to diet-induced obesity. J Clin Invest. 114:1354-60. (doi: 10.1172/JCI20631). 
Errata published in JCI 114:1686-7. 
10.  De Luca M, Klimentidis YC, Casazza K, Chambers MM, Cho R, Harbison ST, Jumbo-Lucioni P, 
Zhang S, Leips J, Fernandez JR. 2010. A conserved role for syndecan family members in the 
regulation of whole-body energy metabolism. PLoS One. 5(6):e11286. doi: 
10.1371/journal.pone.0011286.  
11. Beauvais DM, Jung O, Yang Y, Sanderson RD, Rapraeger AC. 2016. Syndecan-1 (CD138) 
suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by synstatin 
IGF1R inhibits tumor growth. Cancer Res. 76:4981-93. (doi: 10.1158/0008-5472.CAN-16-0232).  
12. Theocharis AD, Skandalis SS, Neill T, Multhaupt HA, Hubo M, Frey H, Gopal S, Gomes A, 
Afratis N, Lim HC et al. 2015. Insights into the key roles of proteoglycans in breast cancer biology 
and translational medicine. Biochim Biophys Acta. 1855:276-300. (doi: 
10.1016/j.bbcan.2015.03.00).  
13. Qiao W, Liu H, Guo W, Li P, Deng M. 2019. Prognostic and clinical significance of syndecan-
1 expression in breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 45:1132-
1137. (doi: 10.1016/j.ejso.2018.12.019).  
14. Rhiner C, Gysi S, Frohli E, Hengartner M O, Hajna A. 2005. Syndecan regulates cell 
migration and axon guidance in C. elegans. Development. 132:4621-4633. 
(doi:10.1242/dev.02042). 
15.    Han S, Schroeder EA, Silva-Garcia CG, Hebestreit K, Mair WB, & Brunet A. 2017. Mono-
unsaturated fatty acids link H3K4me3 modifiers to C. elegans lifespan. Nature.  544:185-190. 
(doi:10.1038/nature21686). 
16.    Knox, J., Moyer, K., Yacoub, N., Soldaat, C., Komosa, M., Vassilieva, K., Wilk, R., Hu, J., 
Vazquez Paz, L.L., Syed, Q., Krause, H.M., Georgescu, M., Jacobs, J.R. 2011. Syndecan contributes 
to heart cell specification and lumen formation during Drosophila cardiogenesis.  Dev. Biol. 356: 
279--290. (doi: 10.1016/j.ydbio.2011.04.006). 
17.  Staudt, N., Molitor, A., Somogyi, K., Mata, J., Curado, S., Eulenberg, K., Meise, M., Siegmund, 
T., Haeder, T., Hilfiker, A. et al. 2005. Gain-of-function screen for genes that affect Drosophila 
muscle pattern formation.  PLoS Genet. 1(4): e55. (doi: 10.1371/journal.pgen.0010055). 
18.  Johnson KG, Ghose A, Epstein E, Lincecum J, O'Connor MB, Van Vactor D. 2004. Axonal 
heparan sulfate proteoglycans regulate the distribution and efficiency of the repellent slit during 
midline axon guidance. Curr Biol. 14:499-504. (doi: 10.1016/j.cub.2004.02.005). 
19.   Johnson KG, Tenney AP, Ghose A, Duckworth AM, Higashi ME, Parfitt K, Marcu O, Heslip TR, 
Marsh JL, Schwarz TL et al. 2006. The HSPGs Syndecan and Dallylike bind the receptor phosphatase 
LAR and exert distinct effects on synaptic development. Neuron. 49:517-31. (doi: 
10.1016/j.neuron.2006.01.026). 
20.    Cammarato A, Ahrens CH, Alayari NN, Qeli E, Rucker J, Reedy MC, Zmasek CM, Gucek M, Cole 
RN, Van Eyk JE, et al. 2011. A mighty small heart: the cardiac proteome of adult Drosophila 
melanogaster. PLoS One. 6(4):e18497. (doi: 10.1371/journal.pone.0018497). 
21.   Aradska, J, Bulat T, Sialana FJ, Birner-Gruenberger R, Erich B, Lubec G. (2015). Gel-free mass 
spectrometry analysis of Drosophila melanogaster heads. Proteomics 15:3356-60. (doi: 
10.1002/pmic.201500092). 
22.    Hienola A, Tumova S, Kulesskiy E, Rauvala H. 2006. N-syndecan deficiency impairs neural 
migration in brain. J Cell Biol. 174:569-580. (doi:10.1083/jcb.200602043). 
23.     Arokiasamy S, Balderstone MJM, De Rossi G, Whiteford JR. 2020. Syndecan-3 in 
Inflammation and Angiogenesis. Front Immunol. 10:3031. (doi: 10.3389/fimmu.2019.03031). 
24.     Regős E, Karászi K, Reszegi A, Kiss A, Schaff Z, Baghy K, Kovalszky I. 2020. Syndecan-1 in Liver 
Diseases. Pathol Oncol Res. 26:813-819. (doi: 10.1007/s12253-019-00617-0). 
25. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, Esko JD. 2009. 
Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of 
triglyceride-rich lipoproteins in mice. J Clin Invest. 119:3236-45. (doi: 10.1172/JCI38251).  
26.     Stepp MA, Gibson HE, Gala PH, Iglesia DD, Pajoohesh-Ganji A, Pal-Ghosh S, Brown M, Aquino 
C, Schwartz AM, Goldberger O, Hinkes MT, Bernfield M. 2002. Defects in keratinocyte activation 
during wound healing in the syndecan-1-deficient mouse. J Cell Sci. 115:4517-31. (doi: 
10.1242/jcs.00128).  
27.      Kato M, Saunders S, Nguyen H, Bernfield M. 1995. Loss of cell surface syndecan-1 causes 
epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 6:559-76. 
(doi: 10.1091/mbc.6.5.559). 
28. Morgan MR, Hamidi H, Bass MD, Warwood S, Ballestrem C, Humphries MJ. 2013. 
Syndecan-4 phosphorylation is a control point for integrin recycling. Dev Cell 24:472-85. (doi: 
10.1016/j.devcel.2013.01.027).  
29. Bass MD, Williamson RC, Nunan RD, Humphries JD, Byron A, Morgan MR, Martin P, 
Humphries MJ. 2011. A syndecan-4 hair trigger initiates wound healing through caveolin- and 
RhoG-regulated integrin endocytosis. Dev Cell. 21:681-93. (doi: 10.1016/j.devcel.2011.08.007). 
30.     Couchman JR, Gopal S, Lim HC, Nørgaard S, Multhaupt HA. 2015.  Fell-Muir Lecture: 
Syndecans: from peripheral coreceptors to mainstream regulators of cell behaviour. Int J Exp 
Pathol. 96:1-10. (doi: 10.1111/iep.12112). 
31.     Okuyama E, Suzuki A, Murata M, Ando Y, Kato I, Takagi Y, Takagi A, Murate T, Saito H, Kojima 
T. 2013. Molecular mechanisms of syndecan-4 upregulation by TNF-α in the endothelium-like 
EAhy926 cells. J Biochem. 154:41-50. (doi: 10.1093/jb/mvt024).  
32.    Zhang Y, Pasparakis M, Kollias G, Simons M. Myocyte-dependent regulation of endothelial 
cell syndecan-4 expression. Role of TNF-alpha. 1999.  J Biol Chem. 274:14786-90. (doi: 
10.1074/jbc.274.21.14786). 
33.     Wang X, Wang H, Yang H, Li J, Cai Q, Shapiro IM, Risbud MV. Tumor necrosis factor-α- and 
interleukin-1β-dependent matrix metalloproteinase-3 expression in nucleus pulposus cells 
requires cooperative signaling via syndecan 4 and mitogen-activated protein kinase-NF-κB axis: 
implications in inflammatory disc disease. 2014. Am J Pathol. 184:2560-72. (doi: 
10.1016/j.ajpath.2014.06.006). 
34.    Clasper S, Vekemans S, Fiore M, Plebanski M, Wordsworth P, David G, Jackson DG. 1999. 
Inducible expression of the cell surface heparan sulfate proteoglycan Syndecan-2 (Fibroglycan) on 
human activated macrophages can regulate fibroblast growth factor action. J Biol Chem. 
274:24113–123. (doi.org/10.1074/jbc.274.34.24113). 
35.    Jang B, Jung H, Chung H, Moon BI, Oh ES. Syndecan-2 enhances E-cadherin shedding and 
fibroblast-like morphological changes by inducing MMP-7 expression in colon cancer cells. 2016. 
Biochem Biophys Res Commun. 477:47-53. (doi: 10.1016/j.bbrc.2016.06.019). 
36. Gopal S, Søgaard P, Multhaupt HA, Pataki C, Okina E, Xian X, Pedersen ME, Stevens T, 
Griesbeck O, Park PW, Pocock R, Couchman JR. 2015. Transmembrane proteoglycans control 
stretch-activated channels to set cytosolic calcium levels. J Cell Biol. 210:1199-211. (doi: 
10.1083/jcb.201501060).  
37.    Binder Gallimidi A, Nussbaum G, Hermano E, Weizman B, Meirovitz A, Vlodavsky I, Götte M, 
Elkin M. 2017. Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced 
colon carcinoma. PLoS One. 12(3):e0174343. (doi: 10.1371/journal.pone.0174343).  
38.    Park PW, Pier GB, Hinkes MT, Bernfield M. Exploitation of syndecan-1 shedding by 
Pseudomonas aeruginosa enhances virulence. Nature. 2001 411:98-102. (doi: 10.1038/35075100).  
39. Tang GL, Weitz K. 2015. Impaired arteriogenesis in syndecan-1(-/-) mice. J Surg Res. 193:22-
7. (doi: 10.1016/j.jss.2014.08.002).  
40. Corti F, Wang Y, Rhodes JM, Atri D, Archer-Hartmann S, Zhang J, Zhuang ZW, Chen D, Wang 
T, Wang Z, Azadi P, Simons M. N-terminal syndecan-2 domain selectively enhances 6-O heparan 
sulfate chains sulfation and promotes VEGFA165-dependent neovascularization. Nat Commun. 
2019 Apr 5;10(1):1562. doi: 10.1038/s41467-019-09605-z. Erratum in: Nat Commun. 2019 May 
7;10(1):2124. REF 173 
41. Kehoe O, Kalia N, King S, Eustace A, Boyes C, Reizes O, Williams A, Patterson A, Middleton J. 
Syndecan-3 is selectively pro-inflammatory in the joint and contributes to antigen-induced arthritis 
in mice. 2014. Arthritis Res Ther. 16:R148.(doi: 10.1186/ar4610). REF185 
42. Fröhling M, Tepasse P, Intemann J, Sambale M, Sherwood J, Paruzel P, Tiemeyer NM, 
Nowacki TM, Brückner M, Mennigen R, et al. 2018. Syndecan-4 modulates epithelial gut barrier 
function and epithelial regeneration in experimental colitis. Inflamm Bowel Dis. 24:2579-2589. 
(doi: 10.1093/ibd/izy248).  
43. Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Denhez F, Detmar M, Goetinck P. 
Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest. 2001 
Jan;107(2):R9-R14. (doi: 10.1172/JCI10559). REF 171 
44. Echtermeyer F, Bertrand J, Dreier R, Meinecke I, Neugebauer K, Fuerst M, Lee YJ, Song YW, 
Herzog C, Theilmeier G, Pap T. 2009. Syndecan-4 regulates ADAMTS-5 activation and cartilage 
breakdown in osteoarthritis. Nat Med. 15:1072-6. (doi: 10.1038/nm.1998). REF 183 
45. Li G, Xie J, Chen J, Li R, Wu H, Zhang X, Chen Q, Gu R, Xu B. 2017. Syndecan-4 deficiency 
accelerates the transition from compensated hypertrophy to heart failure following pressure 
overload. Cardiovasc Pathol. 28:74-79. (doi: 10.1016/j.carpath.2017.03.008).  
46. Tanino Y, Wang X, Nikaido T, Misa K, Sato Y, Togawa R, Kawamata T, Kikuchi M, Frevert 
CW, Tanino M, et al. Syndecan-4 Inhibits the Development of Pulmonary Fibrosis by Attenuating 
TGF-β Signaling. 2019. Int J Mol Sci. 20:4989. (doi: 10.3390/ijms20204989). REF 195 
47. Ishiguro K, Kadomatsu K, Kojima T, Muramatsu H, Iwase M, Yoshikai Y, Yanada M, 
Yamamoto K, Matsushita T, Nishimura M, et al. 2001. Syndecan-4 deficiency leads to high 
mortality of lipopolysaccharide-injected mice.. J Biol Chem. 276(50):47483-8. (doi: 
10.1074/jbc.M106268200). 
48.     Chakravarti R, Adams JC. 2006. Comparative genomics of the syndecans defines an ancestral 
genomic context associated with matrilins in vertebrates. BMC Genomics. 7:83. (doi: 
10.1186/1471-2164-7-83). 
49.      Oh ES, Woods A, Couchman JR. 1997. Multimerization of the cytoplasmic domain of 
syndecan-4 is required for its ability to activate protein kinase C. J Biol Chem 272:11805-11. (doi: 
10.1074/jbc.272.18.11805). 
50. Chen K, Williams KJ. 2013. Molecular mediators for raft-dependent endocytosis of 
syndecan-1, a highly conserved, multifunctional receptor. J Biol Chem. 288:13988-99. (doi: 
10.1074/jbc.M112.444737).  
51. Kawaguchi Y, Takeuchi T, Kuwata K, Chiba J, Hatanaka Y, Nakase I, Futaki S. 2016. 
Syndecan-4 Is a receptor for clathrin-mediated endocytosis of arginine-rich cell-penetrating 
peptides. Bioconjug Chem. 27:1119-30. (doi: 10.1021/acs.bioconjchem.6b00082).  
52. Kirsch N, Chang LS, Koch S, Glinka A, Dolde C, Colozza G, Benitez MDJ, De Robertis EM, 
Niehrs C. 2017. Angiopoietin-like 4 Is a Wnt Signaling antagonist that promotes LRP6 turnover. Dev 
Cell. 43:71-82.e6. (doi: 10.1016/j.devcel.2017.09.011).  
53. Yao W, Rose JL, Wang W, Seth S, Jiang H, Taguchi A, Liu J, Yan L, Kapoor A, Hou P et al. 
2019. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 568:410-
414. (doi: 10.1038/s41586-019-1062-1).  
54. Lim HC, Multhaupt HA, Couchman JR. 2015. Cell surface heparan sulfate proteoglycans 
control adhesion and invasion of breast carcinoma cells. Mol Cancer. 14:15. (doi: 10.1186/s12943-
014-0279-8). 
55. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere 
F, Coomans C, Vermeiren E, Zimmermann P, David G. 2012. Syndecan-syntenin-ALIX regulates the 
biogenesis of exosomes. Nat Cell Biol. 14:677-85. (doi: 10.1038/ncb2502). 
56. Imjeti NS, Menck K, Egea-Jimenez AL, Lecointre C, Lembo F, Bouguenina H, Badache A, 
Ghossoub R, David G, Roche S, Zimmermann P. 2017. Syntenin mediates SRC function in exosomal 
cell-to-cell communication. Proc Natl Acad Sci U S A. 114:12495-12500. (doi: 
10.1073/pnas.1713433114). 
57. Addi C, Presle A, Frémont S, Cuvelier F, Rocancourt M, Milin F, Schmutz S, Chamot-Rooke J, 
Douché T, Duchateau M et al. 2020. The Flemmingsome reveals an ESCRT-to-membrane coupling 
via ALIX/syntenin/syndecan-4 required for completion of cytokinesis. Nat Commun. 11:1941. (doi: 
10.1038/s41467-020-15205-z).  
58. Gondelaud F, Ricard-Blum S. 2019. Structures and interactions of syndecans. FEBS J. 
286:2994-3007. (doi: 10.1111/febs.14828).  
59. Lee D, Oh ES, Woods A, Couchman JR, Lee W. 1998. Solution structure of a syndecan-4 
cytoplasmic domain and its interaction with phosphatidylinositol 4,5-bisphosphate. J Biol Chem. 
273:13022-9. (doi: 10.1074/jbc.273.21.13022).  
60. Dovas A, Choi Y, Yoneda A, Multhaupt HA, Kwon SH, Kang D, Oh ES, Couchman JR. 2010. 
Serine 34 phosphorylation of rho guanine dissociation inhibitor (RhoGDIalpha) links signaling from 
conventional protein kinase C to RhoGTPase in cell adhesion. J Biol Chem. 285:23296-308. (doi: 
10.1074/jbc.M109.098129).  
61. Bass MD, Morgan MR, Roach KA, Settleman J, Goryachev AB, Humphries MJ. 2008. 
p190RhoGAP is the convergence point of adhesion signals from alpha 5 beta 1 integrin and 
syndecan-4. J Cell Biol. 181:1013-26. (doi: 10.1083/jcb.200711129). 
62. Kim EY, Roshanravan H, Dryer SE. 2015. Syndecan-4 ectodomain evokes mobilization of 
podocyte TRPC6 channels and their associated pathways: an essential role for integrin signaling. 
Biochim Biophys Acta. 1853:2610-20. (doi: 10.1016/j.bbamcr.2015.07.011). 
63. Zandonadi FS, Castañeda Santa Cruz E, Korvala J. 2019. New SDC function prediction based 
on protein-protein interaction using bioinformatics tools. Comput Biol Chem. 83:107087. (doi: 
10.1016/j.compbiolchem.2019.107087). 
64. Lindahl U, Couchman J, Kimata K, Esko JD. 2017. Proteoglycans and sulfated 
glycosaminoglycans. In: Essentials of Glycobiology, 3rd ed. Cold Spring Harbor (NY): Cold Spring 
Harbor Laboratory Press; 2015–2017. Chapter 17. 
65. Xu D, Esko JD. 2014. Demystifying heparan sulfate-protein interactions. Annu Rev Biochem. 
83:129-57. (doi: 10.1146/annurev-biochem-060713-035314).  
66.  Qiu H, Shi S, Yue J, Xin M, Nairn AV, Lin L, Liu X, Li G, Archer-Hartmann SA, Dela Rosa M et 
al. 2018. A mutant-cell library for systematic analysis of heparan sulfate structure-function 
relationships. Nat Methods. 11:889-899. (doi: 10.1038/s41592-018-0189-6).  
67. Mulloy B, Lever R, Page CP. 2017. Mast cell glycosaminoglycans. Glycoconj J. 34:351-361. 
(doi: 10.1007/s10719-016-9749-0).  
68.  Esko JD, Prestegard JH, Linhardt RJ. 2017. Proteins that bind sulfated glycosaminoglycans. 
In: Essentials of Glycobiology, Cold Spring Harbor, Chapter 38. 
69. Van den Born J, Salmivirta K, Henttinen T, Ostman N, Ishimaru T, Miyaura S, Yoshida K, 
Salmivirta M. 2005. Novel heparan sulfate structures revealed by monoclonal antibodies. J Biol 
Chem. 280:20516-23. (doi: 10.1074/jbc.M502065200).  
70. Damen LAA, van de Westerlo EMA, Versteeg EMM, van Wessel T, Daamen WF, van 
Kuppevelt TH. 2020. Construction and evaluation of an antibody phage display library targeting 
heparan sulfate. Glycoconj J. 37:445-455. (doi: 10.1007/s10719-020-09925-z). 
71. Aquino RS, Hui-Fang Teng Y, Park PW. 2018. Glycobiology of syndecan-1 in bacterial 
infection. Biochem Soc Trans. 46:371-7. (doi: 10.1042/BST20170395). 
72. Pereira MA, et al. 2016. Placental sequestration of Plasmodium falciparum malaria 
parasites is mediated by the interaction between VAR2CSA and chondroitin sulfate A on Syndecan-
1. PLoS Pathog. 12: e1005831. 
73. Jung O, Beauvais DM, Adams KM, Rapraeger AC. 2019. VLA-4 phosphorylation during 
tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1. J Cell 
Science 132, jcs232645. (doi:10.1242/jcs.232645). 
74. Wang H, Jin H, Rapraeger AC. 2015. Syndecan-1 and syndecan-4 capture epidermal growth 
factor receptor family members and the α3β1 integrin via binding sites in their ectodomains: novel 
synstatins prevent kinase capture and inhibit α6β4-integrin-dependent epithelial cell motility. J 
Biol Chem 290:26103-13. (doi:10.1074/jbc.M115.679084).  
75.  Matsuo I, Kimura-Yoshida C. 2014. Extracellular distribution of diffusible growth factors 
controlled by heparan sulfate proteoglycans during mammalian embryogenesis. Philos Trans R Soc 
B Biol Sci. 369:20130545. (doi.org/10.1098/rstb.2013.0545). 
76.  Olwin BB, Rapraeger A. 1992. Repression of myogenic differentiation by aFGF, bFGF, and K-
FGF is dependent on cellular heparan sulfate. J Cell Biol. 118:631-9. (doi: 10.1083/jcb.118.3.631).  
77. Nakato H, Li JP. 2016. Functions of heparan sulfate proteoglycans in development: insights 
from Drosophila models. Int Rev Cell Mol Biol. 325:275-93. (doi: 10.1016/bs.ircmb.2016.02.008).  
78. Jenkins LM, Horst B, Lancaster CL, Mythreye K. 2018. Dually modified transmembrane 
proteoglycans in development and disease. Cytokine Growth Factor Rev. 39:124-136. (doi: 
10.1016/j.cytogfr.2017.12.003).   
79.  Gallagher J. 2015. Fell-Muir Lecture: Heparan sulphate and the art of cell regulation: a 
polymer chain conducts the protein orchestra. Int J Exp Pathol. 96:203-31. 
(doi:10.1111/iep.12135).  
80.   Escobar Galvis ML, Jia J, Zhang X, Jastrebova N, Spillmann D, Gottfridsson E, van Kuppevelt 
TH, Zcharia E, Vlodavsky I, Lindahl U, Li J-P. 2007. Transgenic or tumor-induced expression of 
heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol. 3:773–778. 
(doi.org/10.1038/nchembio.2007.41). 
81.  Settembre C, Arteaga-Solis E, McKee MD, de Pablo R, Al Awqati Q, Ballabio A, Karsenty G. 
2008. Proteoglycan desulfation determines the efficiency of chondrocyte autophagy and the 
extent of FGF signaling during endochondral ossification. Genes Dev. 22:2645–2650. 
(doi.org/10.1101/gad.1711308). 
82.  Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson CP. 2004. QSulf1, a 
heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm 
induction and angiogenesis. Proc Natl Acad Sci 101:4833–4838. 
(doi.org/10.1073/pnas.0401028101). 
83.  Shimokawa K, Kimura-Yoshida C, Nagai N, Mukai K, Matsubara K, Watanabe H, Matsuda Y, 
Mochida K, Matsuo I. 2011. Cell Surface Heparan Sulfate Chains Regulate Local Reception of FGF 
Signaling in the Mouse Embryo. Dev Cell 21, 257–272. (doi.org/10.1016/j.devcel.2011.06.027). 
84.  Nikitovic D, Assouti M, Sifaki M, Katonis P, Krasagakis K, Karamanos NK, Tzanakakis GN. 
2008. Chondroitin sulfate and heparan sulfate-containing proteoglycans are both partners and 
targets of basic fibroblast growth factor-mediated proliferation in human metastatic melanoma 
cell lines. Int. J. Biochem. Cell Biol. 40:72–83. (doi.org/10.1016/j.biocel.2007.06.019). 
85.  Nikitovic D, Mytilinaiou M, Berdiaki A, Karamanos NK, Tzanakakis GN. 2014. Heparan 
sulfate proteoglycans and heparin regulate melanoma cell functions. Biochim. Biophys. Acta BBA - 
Gen. Subj. 1840:2471–2481. (doi.org/10.1016/j.bbagen.2014.01.031). 
86. Lord MS, Chuang CY, Melrose J, Davis JM, Iozzo RV, Whitelock JM. 2014. The role of 
vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signalling. 
Matrix Biol. 35:112-22. (doi: 10.1016/j.matbio.2014.01.06). 
87.  Chuang CY, Lord MS, Melrose J, Rees MD, Knox SM, Freeman C, Iozzo RV, Whitelock JM. 
2010. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived 
perlecan. Biochemistry 49:5524–32. (doi.org/10.1021/bi1005199). 
88.     Vlodavsky I, Ilan N, Sanderson RD. 2020. Forty Years of Basic and Translational Heparanase 
Research. Adv Exp Med Biol. 1221:3-59. (doi: 10.1007/978-3-030-34521-1). 
89.     Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, Ilan N. 2016. 
Heparanase: From basic research to therapeutic applications in cancer and inflammation. Drug 
Resist Updat. 29:54-75. (doi: 10.1016/j.drup.2016.10.001).  
90.    Teixeira FCOB, Götte M. 2020. Involvement of syndecan-1 and heparanase in cancer and 
inflammation. Adv Exp Med Biol. 1221:97-135. (doi: 10.1007/978-3-030-34521-1_4). 
91.     Vlodavsky I, Gross-Cohen M, Weissmann M, Ilan N, Sanderson RD. 2018. Opposing Functions 
of Heparanase-1 and Heparanase-2 in Cancer Progression. Trends Biochem Sci. 43:18-31. (doi: 
10.1016/j.tibs.2017.10.007). 
92.     El Masri R, Crétinon Y, Gout E, Vivès RR. 2020. HS and Inflammation: A Potential Playground 
for the Sulfs? Front Immunol. 11:570. (doi: 10.3389/fimmu.2020.00570).  
93.     Lanzi C, Zaffaroni N, Cassinelli G. 2017. Targeting heparan sulfate proteoglycans and their 
modifying enzymes to enhance anticancer chemotherapy efficacy and overcome drug resistance. 
Curr Med Chem. 24:2860-2886. (doi: 10.2174/0929867324666170216114248). 
94.   Pataki CA, Couchman JR, Brábek J. 2015. Wnt signaling cascades and the roles of syndecan 
proteoglycans. J Histochem Cytochem. 63:465-80. (doi: 10.1369/0022155415586961).  
95.  Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S, Bernfield 
M. 2000. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet. 
25:329–32. (doi.org/10.1038/77108). 
96.  Haerry TE, Heslip TR, Marsh JL, O'Connor MB. 1997. Defects in glucuronate biosynthesis 
disrupt Wingless signaling in Drosophila. Development. 124:3055-64. 
97. Okawara B, Glinka A, Niehrs C. 2011. Rspo3 binds syndecan 4 and induces Wnt/PCP 
signaling via clathrin-mediated endocytosis to promote morphogenesis. Dev Cell. 20:303-14. (doi: 
10.1016/j.devcel.2011.01.006).  
98. Muñoz R, Moreno M, Oliva C, Orbenes C, Larraín J. 2006. Syndecan-4 regulates non-
canonical Wnt signalling and is essential for convergent and extension movements in Xenopus 
embryos. Nat Cell Biol. 8:492-500. (doi: 10.1038/ncb1399).  
99.  Zhang L, David G, Esko JD. 1995. Repetitive Ser-Gly sequences enhance heparan sulfate 
assembly in proteoglycans. J Biol Chem. 270: 27127–135. (doi.org/10.1074/jbc.270.45.27127). 
100.  Bentzinger  CF , Wang  YX, von Maltzahn J, Soleimani VD,  Yin H, Rudnicki MA. 2013. 
Fibronectin regulates Wnt7a signaling and satellite cell expansion Cell Stem Cell 12:75-87.  (doi: 
10.1016/j.stem.2012.09.015). 
101. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson Jr CP. 2001. Regulation of 
Wnt signaling and embryo patterning by an extracellular sulfatase. Science 293:1663-6.  (doi: 
10.1126/science.293.5535.1663).    
102.  Ai X, Do A-T, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP. 2003. QSulf1 
remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt 
signaling. J Cell Biol. 162:341–51. (doi.org/10.1083/jcb.200212083). 
103.  Capurro M, Martin T, Shi W, Filmus J. 2014. Glypican-3 binds to Frizzled and plays a direct 
role in the stimulation of canonical Wnt signaling. J. Cell Sci. 127:1565–1575. 
(doi.org/10.1242/jcs.140871). 
104. Li N, Wei L, Liu X, Bai H, Ye Y, Li D, Li N, Baxa U, Wang Q, Lv L et al. 2019. A Frizzled-Like 
Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular 
Carcinoma Tumor Growth in Mice. Hepatology. 70:1231-1245. (doi: 10.1002/hep.30646).  
105. Ren Z, Van Andel H, De Lau W, Hartholt RB, Maurice MM, Clevers H, Kersten MJ, 
Spaargaren M, Pals ST. 2018. Syndecan-1 promotes Wnt/b-catenin signalling in multiple myeloma 
by presenting Wnts and R-spondins. Blood 131:982-994. (doi.org/10.1182/blood-2017-07-
797050). 
106. Xie Y, Zamponi R, Charlat O, et al. 2013. Interaction with both ZNRF3 and LGR4 is required 
for the signalling activity of R-spondin. EMBO Rep. 14:1120-6. (doi:10.1038/embor.2013.167). 
107. Dubey R, Van Kerkhof P, Jordens I, Malinauskas T, Pusapati GV, McKenna JK, Li D, Carette 
JE, Ho M, Siebold C et al. 2020. R-spondins engage heparin sulfate proteoglycans to potentiate 
WNT signalling. Elife 9, e54469. (doi: 10.7554/eLife.54469). 
108. Giráldez AJ, Copley RR, Cohen SM. 2002. HSPG modification by the secreted sezyme notum 
shapes the Wingless morphogen gradient. Dev Cell 2:667–676. (doi.org/10.1016/S1534-
5807(02)00180-6). 
109. Kakugawa S, Langton PF, Zebisch M, Howell S, Chang TH, Liu Y, Feizi T, Bineva G, O'Reilly N, 
Snijders AP, Jones EY, Vincent JP. 2015. Notum deacylates Wnt proteins to suppress signalling 
activity. Nature 519:187-192. (doi: 10.1038/nature14259).  
110. Shi W, Kaneiwa T, Cydzik M, Gariepy J, Filmus J. 2020. Glypican-6 stimulates intestinal 
elongation by simultaneously regulating Hedgehog and non-canonical Wnt signaling. Matrix Biol. 
88:19-32. (doi: 10.1016/j.matbio.2019.11.002).  
111. McGough IJ, Vecchia L, Bishop B, Malinauskas T, Beckett K, Joshi D, O'Reilly N, Siebold C, 
Jones EY, Vincent JP. 2020. Glypicans shield the Wnt lipid moiety to enable signalling at a distance. 
Nature. 585:85-90. (doi: 10.1038/s41586-020-2498-z).  
112. Jeng KS, Chang CF, Lin SS. 2020. Sonic Hedgehog Signaling in Organogenesis, Tumors, and 
Tumor Microenvironments. Int J Mol Sci. 21:758. (doi: 10.3390/ijms21030758).  
113. Groves I, Placzek M, Fletcher AG. 2020. Of mitogens and morphogens: modelling Sonic 
Hedgehog mechanisms in vertebrate development. Philos Trans R Soc Lond B Biol Sci. 
375:20190660. (doi: 10.1098/rstb.2019.0660).  
114. Chang SC, Mulloy B, Magee AI, Couchman JR. 2011. Two distinct sites in sonic Hedgehog 
combine for heparan sulfate interactions and cell signaling functions. J Biol Chem. 286:44391-402. 
(doi: 10.1074/jbc.M111.285361. ). 
115. Li F, Shi W, Capurro M, Filmus J. 2011. Glypican-5 stimulates rhabdomyosarcoma cell 
proliferation by activating Hedgehog signaling. J Cell Biol. 192:691-704. (doi: 
10.1083/jcb.201008087). 
116. Park Y, Rangel C, Reynolds MM, Caldwell MC, Johns M, Nayak M, Welsh CJ, McDermott S, 
Datta S. 2003. Drosophila perlecan modulates FGF and hedgehog signals to activate neural stem 
cell division. Dev Biol. 253:247-57. (doi: 10.1016/s0012-1606(02)00019-2).  
117. Okamoto O, Bachy S, Odenthal U, Bernaud J, Rigal D, Lortat-Jacob H, Smyth N, Rousselle P. 
2003. Normal human keratinocytes bind to the alpha3LG4/5 domain of unprocessed laminin-5 
through the receptor syndecan-1. J Biol Chem. 278:44168-77. (doi: 10.1074/jbc.M300726200).  
118. Deepa SS, Yamada S, Zako M, Goldberger O, Sugahara K. 2004. Chondroitin sulfate chains 
on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are 
structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth 
factors. A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth 
factor. J Biol Chem. 279:37368-76. (doi: 10.1074/jbc.M403031200). 
119. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. 1991. Cell 64:841-8. (doi: 
10.1016/0092-8674(91)90512-w.) 
120. Chanana B, Steigemann P, Jäckle H, Vorbrüggen G. 2009. Reception of Slit requires only the 
chondroitin-sulphate-modified extracellular domain of Syndecan at the target cell surface. Proc 
Natl Acad Sci U S A. 106:11984-8. (doi: 10.1073/pnas.0901148106). . 
121. Eriksson AS, Spillmann D. 2012. The mutual impact of syndecan-1 and its 
glycosaminoglycan chains--a multivariable puzzle. J Histochem Cytochem. 60:936-942. 
(doi:10.1369/0022155412460242).  
122.     Gopal S. 2020. Syndecans in inflammation at a glance. Front Immunol. 11:227. (doi: 
10.3389/fimmu.2020.00227). 
123.     Bertrand J, Bollmann M. 2019. Soluble syndecans: biomarkers for diseases and therapeutic 
options. Br J Pharmacol. 176:67-81. (doi: 10.1111/bph.14397).  
124.     Rangarajan S, Richter JR, Richter RP, Bandari SK, Tripathi K, Vlodavsky I, Sanderson RD. 
2020. Heparanase-enhanced ahedding of ayndecan-1 and Its role in driving disease pathogenesis 
and progression. J Histochem Cytochem. 68:823-840. (doi: 10.1369/0022155420937087).  
125.     Jung O, Trapp-Stamborski V, Purushothaman A, Jin H, Wang H, Sanderson RD, Rapraeger 
AC. 2016. Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells 
activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis 
5(2):e202. (doi: 10.1038/oncsis.2016.5).  
126.     De Rossi G, Whiteford JR. 2013. Novel insight into the biological functions of syndecan 
ectodomain core proteins. Biofactors. 39:374-82. (doi: 10.1002/biof.1104).  
127.     Rapraeger AC. 2013. Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 
integrin complex in tumorigenesis and angiogenesis. FEBS J. 280:2207-15. (doi: 
10.1111/febs.12160).  
128.     Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De Strooper B, David G. 2003. 
Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates 
cytosolic signaling. J Biol Chem. 278:48651-7. (doi: 10.1074/jbc.M308424200).  
129.     Jang B, Jung H, Choi S, Lee YH, Lee ST, Oh ES. 2017. Syndecan-2 cytoplasmic domain up-
regulates matrix metalloproteinase-7 expression via the protein kinase Cgamma-mediated 
FAK/ERK signaling pathway in colon cancer. J Biol Chem 292: 16321-16332. (doi: 
10.1074/jbc.M117.793752) 
130.     Volta M, Calza S, Roberts AM, Roberts RG. 2010. Characterisation of the interaction 
between syndecan-2, neurofibromin and CASK: dependence of interaction on syndecan 
dimerization. Biochem Biophys Res Commun. 391:1216-21. (doi: 10.1016/j.bbrc.2009.12.043). 
131. Bernfield M, Hinkes MT, Gallo RL. 1993. Developmental expression of the syndecans: 
possible function and regulation. Dev Suppl. 205-12. 
132. Schulz JG, Ceulemans H, Caussinus E, Baietti MF, Affolter M, Hassan BA, David G. 2011. 
Drosophila syndecan regulates tracheal cell migration by stabilizing Robo levels. EMBO Rep. 
12:1039-46. (doi: 10.1038/embor.2011.153).  
133. Xian X, Gopal S, Couchman JR. 2010. Syndecans as receptors and organizers of the 
extracellular matrix. Cell Tissue Res. 339:31-46. (doi:10.1007/s00441-009-0829-3). 
134. Couchman JR, Pataki CA. 2012. An introduction to proteoglycans and their localization. J 
Histochem Cytochem. 60:885-897. (doi:10.1369/0022155412464638). 
135. Minniti AN, Labarca M, Hurtado C, Brandan E. 2004. Caenorhabditis elegans syndecan 
(SDN-1) is required for normal egg laying and associates with the nervous system and the vulva. J 
Cell Sci. 117: 5179-5190. (doi:10.1242/jcs.01394). 
136. Horowitz A, Simons M. 1998. Regulation of syndecan-4 phosphorylation in vivo. J Biol 
Chem. 273:10914-10918. (doi:10.1074/jbc.273.18.10914). 
137. Saied-Santiago K, Townley RA, Attonito JD, da Cunha DS, Díaz-Balzac CA, Tecle E, Bülow HE. 
2017. Coordination of Heparan Sulfate Proteoglycans with Wnt Signaling To Control Cellular 
Migrations and Positioning in Caenorhabditis elegans. Genetics. 206:1951-1967. doi: 
10.1534/genetics.116.198739.  
138. Blanchette CR, Perrat PN, Thackeray A, Benard CY. 2015. Glypican Is a Modulator of Netrin-
Mediated Axon Guidance. PLoS Biol. 13:e1002183. (doi:10.1371/journal.pbio.1002183). 
139. Levin M, Hashimshony T, Wagner F, Yanai I. 2012. Developmental milestones punctuate 
gene expression in the Caenorhabditis embryo. Dev Cell 22:1101-1108. 
(doi:10.1016/j.devcel.2012.04.004). 
140. Tomancak P, Beaton A, Weiszmann R, Kwan E, Shu S, Lewis SE, Richards S, Ashburner M, 
Hartenstein V, Celniker SE, Rubin GM. 2002. Systematic determination of patterns of gene 
expression during Drosophila embryogenesis. Genome Biol. 3:RESEARCH0088. (doi: 10.1186/gb-
2002-3-12-research0088). 
141. Weiszmann R, Hammonds AS, Celniker SE. 2009.Determination of gene expression patterns 
using high-throughput RNA in situ hybridization to whole-mount Drosophila embryos. Nat Protoc. 
4:605-618. (doi:10.1038/nprot.2009.55). 
142. Olson SK, Bishop JR, Yates JR, Oegema K, Esko JD. 2006. Identification of novel chondroitin 
proteoglycans in Caenorhabditis elegans: embryonic cell division depends on CPG-1 and CPG-2. J 
Cell Biol. 173:985-94. (doi: 10.1083/jcb.200603003).  
143. Diaz-Balzac CA, Lazaro-Pena MI, Tecle E, Gomez N, Bulow HE. 2014. Complex cooperative 
functions of heparan sulfate proteoglycans shape nervous system development in Caenorhabditis 
elegans. G3 (Bethesda). 4:1859-1870. (doi:10.1534/g3.114.012591). 
144. Hudson ML, Kinnunen T, Cinar HN, Chisholm AD. 2006. C. elegans Kallmann syndrome 
protein KAL-1 interacts with syndecan and glypican to regulate neuronal cell migrations. Dev Biol. 
294:352-365. (doi:10.1016/j.ydbio.2006.02.036). 
145. White JG, Southgate E, Thomson JN, Brenner S. 1986. The structure of the nervous system 
of the nematode Caenorhabditis elegans. Philos Trans R Soc Lond B Biol Sci. 314:1-340. 
(doi:10.1098/rstb.1986.0056). 
146. Wadsworth WG, Bhatt H, Hedgecock EM. 1996. Neuroglia and pioneer neurons express 
UNC-6 to provide global and local netrin cues for guiding migrations in C. elegans. Neuron. 16:35-
46. (doi:10.1016/s0896-6273(00)80021-5). 
147. Kinnunen TK. 2014. Combinatorial roles of heparan sulfate proteoglycans and heparan 
sulfates in Caenorhabditis elegans neural development. PLoS One. 9, e102919. 
(doi:10.1371/journal.pone.0102919). 
148. Steigemann P, Molitor A, Fellert S, Jackle H, Vorbruggen G.2004. Heparan sulfate 
proteoglycan syndecan promotes axonal and myotube guidance by slit/robo signaling. Curr Biol. 
14:225-230. (doi:10.1016/j.cub.2004.01.006). 
149. Chanana B, Steigemann P, Jackle H, Vorbruggen G. 2009. Reception of Slit requires only the 
chondroitin-sulphate-modified extracellular domain of Syndecan at the target cell surface. Proc 
Natl Acad Sci U S A. 106:11984-11988. (doi:10.1073/pnas.0901148106). 
150.  Hussain SA, Piper M, Fukuhara N, Strochlic L, Cho G, Howitt JA, Ahmed Y, Powell AK, 
Turnbull JE, Holt CE, Hohenester E. 2016. A molecular mechanism for the heparan sulfate 
dependence of slit-robo signaling. J Biol Chem. 281:39693-8. (doi: 10.1074/jbc.M609384200).  
151. Pérez C, Sawmiller D, Tan J. 2016. The role of heparan sulfate deficiency in autistic 
phenotype: potential involvement of Slit/Robo/srGAPs-mediated dendritic spine formation. Neural 
Dev. 11:11. (doi: 10.1186/s13064-016-0066-x).  
152. Kamimura K, Maeda N. 2017. Heparan sulfate proteoglycans in Drosophila neuromuscular 
development. Biochim Biophys Acta Gen Subj. 1861:2442-2446. 
(doi:10.1016/j.bbagen.2017.06.015). 
153. Matthews HK, Marchant L, Carmona-Fontaine C, Kuriyama S, Larraín J, Holt MR, Parsons M, 
Mayor R. 2008. Directional migration of neural crest cells in vivo is regulated by Syndecan-4/Rac1 
and non-canonical Wnt signaling/RhoA. Development. 135:1771-80. (doi: 10.1242/dev.01735).  
154. Luo N, Li H, Xiang B, Qiao L, He J, Ji Y, Liu Y, Li S, Lu R, Li Y et al. Syndecan-4 modulates the 
proliferation of neural cells and the formation of CaP axons during zebrafish embryonic 
neurogenesis. Sci Rep. 2016 6:25300. (doi: 10.1038/srep25300).  
155. Schwabiuk M, Coudiere L, Merz DC. 2009. SDN-1/syndecan regulates growth factor 
signaling in distal tip cell migrations in C. elegans. Dev Biol. 334:235-242. 
(doi:10.1016/j.ydbio.2009.07.020). 
156. Hubbard EJ, Greenstein D. 2005. Introduction to the germ line. WormBook. 1-4. 
doi:10.1895/(wormbook.1.18.1). 
157. Pisconti A, Cornelison DD, Olguin HC, Antwine TL, Olwin BB. 2010. Syndecan-3 and Notch 
cooperate in regulating adult myogenesis. J Cell Biol. 190:427-441. (doi:10.1083/jcb.201003081). 
158. Wang Q, Yang L, Alexander C, Temple S. 2012. The niche factor syndecan-1 regulates the 
maintenance and proliferation of neural progenitor cells during mammalian cortical development. 
PLoS One. 7  e42883. (doi:10.1371/journal.pone.0042883). 
159. Lendorf ME, Manon-Jensen T, Kronqvist P, Multhaupt HA, Couchman JR. 2011. Syndecan-1 
and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem. 59:615-
629. (doi:10.1369/0022155411405057). 
160. Couchman J R, Gopal S, Lim HC, Norgaard S, Multhaupt, HA .2015. Syndecans: from 
peripheral coreceptors to mainstream regulators of cell behaviour. Int J Exp Pathol. 96:1-10. 
(doi:10.1111/iep.12112). 
161. Afratis NA, Nikitovic D, Multhaupt HA, Theocharis AD, Couchman JR, Karamanos NK. 2017. 
Syndecans - key regulators of cell signaling and biological functions. FEBS J. 284:27-41. doi: 
10.1111/febs.13940.  
162. Chung H, Multhaupt HA, Oh ES, Couchman JR. 2016. Minireview: Syndecans and their 
crucial roles during tissue regeneration. FEBS Lett. 590:2408-2417. (doi:10.1002/1873-
3468.12280). 
163. Drzeniek Z, Siebertz B, Stöcker G, Just U, Ostertag W, Greiling H, Haubeck HD. 1997. 
Proteoglycan synthesis in haematopoietic cells: isolation and characterization of heparan sulphate 
proteoglycans expressed by the bone-marrow stromal cell line MS-5. Biochem J.327:473-80. (doi: 
10.1042/bj3270473).  
164. Yin H, Price F, Rudnicki MA. 2013. Satellite cells and the muscle stem cell niche. Physiol 
Rev. 93:23-67. (doi:10.1152/physrev.00043.2011). 
165. Cornelison DD, Filla MS, Stanley HM, Rapraeger AC, Olwin BB. 2001. Syndecan-3 and 
syndecan-4 specifically mark skeletal muscle satellite cells and are implicated in satellite cell 
maintenance and muscle regeneration. Dev Biol. 239, 79-94. (doi:10.1006/dbio.2001.0416). 
166. Casar JC, Cabello-Verrugio C, Olguin H, Aldunate R, Inestrosa NC, Brandan E. 2004. Heparan 
sulfate proteoglycans are increased during skeletal muscle regeneration: requirement of 
syndecan-3 for successful fiber formation. J Cell Sci. 117:73-84. (doi: 10.1242/jcs.00828).  
167. Pisconti A, Bernet JD, Olwin BB. 2012. Syndecans in skeletal muscle development, 
regeneration and homeostasis. Muscles Ligaments Tendons J. 2, 1-9. 
168. Pisconti A, Banks GB, Babaeijandaghi F, Betta ND, Rossi FM, Chamberlain JS, Olwin BB. 
2016. Loss of niche-satellite cell interactions in syndecan-3 null mice alters muscle progenitor cell 
homeostasis improving muscle regeneration. Skelet Muscle. 4;6:34. (doi: 10.1186/s13395-016-
0104-8).  
169. Inatani M, Haruta M, Honjo M, Oohira A, Kido N, Takahashi M, Honda Y, Tanihara H. 2001. 
Upregulated expression of N-syndecan, a transmembrane heparan sulfate proteoglycan, in 
differentiated neural stem cells. Brain Res. 30; 920:217-21. (doi: 10.1016/s0006-8993(01)02856-6). 
170. Mooij HL, Cabrales P, Bernelot Moens SJ, Xu D, Udayappan SD, Tsai AG, van der Sande MA, 
de Groot E, Intaglietta M, Kastelein JJ, Dallinga-Thie GM, Esko JD, Stroes ES, Nieuwdorp M. 2014. 
Loss of function in heparan sulfate elongation genes EXT1 and EXT 2 results in improved nitric 
oxide bioavailability and endothelial function. J Am Heart Assoc. 3:e001274. (doi: 
10.1161/JAHA.114.001274). 
171.  Yang Y, Haeger SM, Suflita MA, Zhang F, Dailey KL, Colbert JF, Ford JA, Picon MA, Stearman 
RS, Lin L et al. 2017. Fibroblast growth factor signaling mediates pulmonary endothelial glycocalyx 
reconstitution. Am J Respir Cell Mol Biol. 56:727-737. (doi: 10.1165/rcmb.2016-0338OC).  
172. Higashi N, Irimura T, Nakajima M. 2020. Heparanase is involved in leukocyte migration. Adv 
Exp Med Biol. 1221:435-444. (doi: 10.1007/978-3-030-34521-1_16). 
173.  Stoler-Barak L, Barzilai S, Zauberman A, Alon R. 2014. Transendothelial migration of 
effector T cells across inflamed endothelial barriers does not require heparan sulfate 
proteoglycans. Int Immunol. 26:315-24. (doi: 10.1093/intimm/dxt076). 
174.  Stoler-Barak L, Petrovich E, Aychek T, Gurevich I, Tal O, Hatzav M, Ilan N, Feigelson SW, 
Shakhar G, Vlodavsky I, Alon R. 2015. Heparanase of murine effector lymphocytes and neutrophils 
is not required for their diapedesis into sites of inflammation. FASEB J. 29:2010-21. (doi: 
10.1096/fj.14-265447). 
175.  Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. 1997. Heparan sulfate 
proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis 
regulated? J Clin Invest. 99:2062-2070. (doi.org/10.1172/JCI119377). 
176.  Weinbaum S, Tarbell JM, Damiano ER. 2007. The structure and function of the endothelial 
glycocalyx layer. Annu Rev Biomed Eng. 9:121-67. (doi: 0.1146/annurev.bioeng.9.060906.151959). 
177. Savery MD, Jiang JX, Park PW, Damiano ER. 2013. The endothelial glycocalyx in syndecan-1 
deficient mice. Microvasc Res. 87:83-91. (doi: 10.1016/j.mvr.2013.02.001).  
178. Abassi Z, Armaly Z, Heyman SN. 2020. Glycocalyx degradation in ischemia-reperfusion 
Injury. Am J Pathol. 190:752-767. (doi: 10.1016/j.ajpath.2019.08.019). 
179. Zhang Y, Wang Z, Liu J, Zhang S, Fei J, Li J, Zhang T, Wang J, Park PW, Chen Y. 2017. Cell 
surface-anchored syndecan-1 ameliorates intestinal inflammation and neutrophil transmigration 
in ulcerative colitis. J Cell Mol Med. 21:13-25. (doi: 10.1111/jcmm.12934).  
180. Kaneider NC, Feistritzer C, Gritti D, Mosheimer BA, Ricevuti G, Patsch JR, Wiedermann CJ. 
2005. Expression and function of syndecan-4 in human platelets. Thromb Haemost. 93:1120-7. 
(doi: 10.1160/TH04-11-0763).  
181. Wang Q, Yang L, Alexander C, Temple S. 2012. The niche factor syndecan-1 regulates the 
maintenance and proliferation of neural progenitor cells during mammalian cortical development. 
PLoS One. 2012;7(8):e42883. (doi: 10.1371/journal.pone.0042883). Erratum in: PLoS One. 
2012;7(11). (doi:10.1371/annotation/76cf3bd3-f842-489f-8ad2-4c016447b84c).  
182. Angsana J, Chen J, Smith S, Xiao J, Wen J, Liu L, Haller CA, Chaikof EL. 2015. Syndecan-1 
modulates the motility and resolution responses of macrophages. Arterioscler Thromb Vasc Biol. 
2015 35:332-40. (doi: 10.1161/ATVBAHA.114.304720).  
183. Boyanovsky BB, Shridas P, Simons M, van der Westhuyzen DR, Webb NR. 2009. Syndecan-4 
mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. J Lipid Res. 
50:641-50. (doi: 10.1194/jlr.M800450-JLR200).  
184. Slimani H, Charnaux N, Mbemba E, Saffar L, Vassy R, Vita C, Gattegno L. 2003. Interaction 
of RANTES with syndecan-1 and syndecan-4 expressed by human primary macrophages. Biochim 
Biophys Acta. 31:1617:80-8. (doi: 10.1016/j.bbamem.2003.09.006). 
185. Wegrowski Y, Milard AL, Kotlarz G, Toulmonde E, Maquart FX, Bernard J. Cell surface 
proteoglycan expression during maturation of human monocyte-derived dendritic cells and 
macrophages.2006. Clin Exp Immunol. 144:485-93. (doi: 10.1111/j.1365-2249.2006.03059.x). 
(Erratum in: Clin Exp Immunol. 2006 145:388).  
186. Averbeck M, Kuhn S, Bühligen J, Götte M, Simon JC, Polte T. 2017. Syndecan-1 regulates 
dendritic cell migration in cutaneous hypersensitivity to haptens. Exp Dermatol. 26:1060-1067. 
(doi: 10.1111/exd.13374).  
187. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, Geijtenbeek TB, Gallay P. 2007. 
Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci U S A. 
104:19464-9. (doi: 10.1073/pnas.0703747104).  
188. Kouwenberg M, Rops A, Bakker-van Bebber M, Diepeveen L, Götte M, Hilbrands L, van der 
Vlag J. 2020. Role of syndecan-1 in the interaction between dendritic cells and T cells. PLoS One. 
15:e0230835. (doi: 10.1371/journal.pone.0230835).  
189. El Ghazal R, Yin X, Johns SC, Swanson L, Macal M, Ghosh P, Zuniga EI, Fuster MM. 2016. 
Glycan Sulfation Modulates Dendritic Cell Biology and Tumor Growth. 2016. Neoplasia 18:294-306. 
(doi: 10.1016/j.neo.2016.04.004).  
190. Dai H, Rahman A, Saxena A, Jaiswal AK, Mohamood A, Ramirez L, Noel S, Rabb H, Jie C, 
Hamad AR. 2015. Syndecan-1 identifies and controls the frequency of IL-17-producing naïve 
natural killer T (NKT17) cells in mice. Eur J Immunol. 45:3045-51. doi: 10.1002/eji.201545532. 
191. Jaiswal AK, Sadasivam M, Hamad ARA. 2018. Unexpected alliance between syndecan-1 and 
innate-like T cells to protect host from autoimmune effects of interleukin-17. World J Diabetes.  
9:220-225. (doi: 10.4239/wjd.v9.i12.220). 
192. McCarron MJ, Park PW, Fooksman DR. 2017. CD138 mediates selection of mature plasma 
cells by regulating their survival. Blood. 129:2749-2759. (doi: 10.1182/blood-2017-01-761643).  
193. Higashi N, Waki M, Sudo Y, Suzuki S, Oku T, Tsuiji M, Tsuji T, Miyagishi M, Takahashi K, 
Nakajima M, Irimura T. 2018. Incorporation, intracellular trafficking and processing of extracellular 
heparanase by mast cells: Involvement of syndecan-4-dependent pathway. Biochem Biophys Res 
Commun. 503:3235-3241. (doi: 10.1016/j.bbrc.2018.08.132).  
194. Nakao S, Komagoe K, Inoue T, Katsu T. 2011. Comparative study of the membrane-
permeabilizing activities of mastoparans and related histamine-releasing agents in bacteria, 
erythrocytes, and mast cells.  Biochim Biophys Acta. 1808:490-7. (doi: 
10.1016/j.bbamem.2010.10.007). 
195. Feistritzer C, Kaneider NC, Sturn DH, Wiedermann CJ. 2004. Syndecan-4-dependent 
migration of human eosinophils. Clin Exp Allergy. 34:696-703. (doi: 10.1111/j.1365-
2222.2004.1853.x). 
196. Nourshargh S, Alon R. 2014.  Leukocyte migration into inflamed tissues. Immunity. 41:694-
707. (doi: 10.1016/j.immuni.2014.10.008).  
197.  Tanino Y, Chang MY, Wang X, Gill SE, Skerrett S, McGuire JK, Sato S, Nikaido T, Kojima T, 
Munakata M et al. 2012. Syndecan-4 regulates early neutrophil migration and pulmonary 
inflammation in response to lipopolysaccharide. Am J Respir Cell Mol Biol. 47:196-202. (doi: 
10.1165/rcmb.2011-0294OC).  
198. Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. 2009. Syndecan-1 regulates 
alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a 
novel peptide inhibitor. J Exp Med. 206:691-705. (doi: 10.1084/jem.20081278).  
199. Beauvais DM, Rapraeger AC. 2010. Syndecan-1 couples the insulin-like growth factor-1 
receptor to inside-out integrin activation. J Cell Sci. 123:3796-807. (doi: 10.1242/jcs.067645).  
200. Rapraeger AC. 2013. Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 
integrin complex in tumorigenesis and angiogenesis. FEBS J. 280:2207-15. (doi: 
10.1111/febs.12160). 
201. Chen E, Hermanson S, Ekker SC. 2004. Syndecan-2 is essential for angiogenic sprouting 
during zebrafish development. Blood. 103:1710-9.( doi: 10.1182/blood-2003-06-1783). 
202. De Rossi G, Whiteford JR. 2014. Syndecans in angiogenesis and endothelial cell biology. 
Biochem Soc Trans. 42:1643-6. (doi: 10.1042/BST20140232). 
203. Tinholt M, Stavik B, Louch W, Carlson CR, Sletten M, Ruf W, Skretting G, Sandset PM, 
Iversen N. 2015. Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, 
and cancer cells. PLoS One. 10:e0117404. (doi: 10.1371/journal.pone.0117404).  
204. Vuong TT, Reine TM, Sudworth A, Jenssen TG, Kolset SO. 2015. Syndecan-4 is a major 
syndecan in primary human endothelial cells in vitro, modulated by inflammatory stimuli and 
involved in wound healing. J Histochem Cytochem. 63:280-92. (doi: 10.1369/0022155415568995).  
205. De Rossi G, Whiteford JR. 2013. A novel role for syndecan-3 in angiogenesis. F1000Res. 
2:270. (doi: 10.12688/f1000research.2-270.v1).  
206. Jannaway M, Yang X, Meegan JE, Coleman DC, Yuan SY. 2019. Thrombin-cleaved syndecan-
3/-4 ectodomain fragments mediate endothelial barrier dysfunction. PLoS One. 14(5):e0214737. 
(doi: 10.1371/journal.pone.0214737). 
207. Lambert J, Makin K, Akbareian S, Johnson R, Alghamdi AAA, Robinson SD, Edwards DR. 
2020. ADAMTS-1 and syndecan-4 intersect in the regulation of cell migration and angiogenesis. J 
Cell Sci. 133:jcs235762. (doi: 10.1242/jcs.235762). 
208. Johns SC, Yin X, Jeltsch M, Bishop JR, Schuksz M, El Ghazal R, Wilcox-Adelman SA, Alitalo K, 
Fuster MM. 2016. Functional importance of a proteoglycan coreceptor in pathologic 
lymphangiogenesis. Circ Res. 119:210-21. (doi: 10.1161/CIRCRESAHA.116.308504).  
209. Wang J, Huang Y, Zhang J, Wei Y, Mahoud S, Bakheet AM, Wang L, Zhou S, Tang J. 2016. 
Pathway-related molecules of VEGFC/D-VEGFR3/NRP2 axis in tumor lymphangiogenesis and 
lymphatic metastasis. Clin Chim Acta. 461:165-71. (doi: 10.1016/j.cca.2016.08.008). 
210. Das S, Monteforte AJ, Singh G, Majid M, Sherman MB, Dunn AK, Baker AB. 2016. Syndecan-
4 enhances therapeutic angiogenesis after hind limb ischemia in mice with Type 2 Diabetes. Adv 
Healthc Mater. 5:1008-13. (doi: 10.1002/adhm.201500993).  
211. Elfenbein A, Lanahan A, Zhou TX, Yamasaki A, Tkachenko E, Matsuda M, Simons M. 2012. 
Syndecan 4 regulates FGFR1 signaling in endothelial cells by directing macropinocytosis. Sci Signal.  
8;5(223):ra36. (doi: 10.1126/scisignal.2002495).  
212. Murakami M, Nguyen LT, Zhuang ZW, Moodie KL, Carmeliet P, Stan RV, Simons M. 2008. 
The FGF system has a key role in regulating vascular integrity. J Clin Invest. 118:3355-66. (doi: 
10.1172/JCI35298).  
213. Patterson AM, Cartwright A, David G, Fitzgerald O, Bresnihan B, Ashton BA, Middleton J. 
2008. Differential expression of syndecans and glypicans in chronically inflamed synovium. Ann 
Rheum Dis. 67:592-601. (doi: 10.1136/ard.2006.063875).  
214. Bertrand J, Stange R, Hidding H, Echtermeyer F, Nalesso G, Godmann L, Timmen M, 
Bruckner P, Dell'Accio F, Raschke MJ  et al. 2013. Syndecan 4 supports bone fracture repair, but 
not fetal skeletal development, in mice. Arthritis Rheum. 65(3):743-52. (doi: 10.1002/art.37817) 
215. Cai P, Lu Z, Jiang T, Wang Z, Yang Y, Zheng L, Zhao J. 2020. Syndecan-4 involves in the 
pathogenesis of rheumatoid arthritis by regulating the inflammatory response and apoptosis of 
fibroblast-like synoviocytes. J Cell Physiol. 235:1746-1758. (doi: 10.1002/jcp.29093). 
216. Doody KM, Stanford SM, Sacchetti C, Svensson MN, Coles CH, Mitakidis N, Kiosses WB, 
Bartok B, Fos C, Cory E et al. 2015. Targeting phosphatase-dependent proteoglycan switch for 
rheumatoid arthritis therapy. Sci Transl Med. 7:288ra76. (doi: 10.1126/scitranslmed.aaa4616).  
217. Endo T, Ito K, Morimoto J, Kanayama M, Ota D, Ikesue M, Kon S, Takahashi D, Onodera T, 
Iwasaki N, Uede T. 2015. Syndecan 4 regulation of the development of autoimmune arthritis in 
mice by modulating B cell migration and germinal center formation. Arthritis Rheumatol. 67:2512-
22. (doi: 10.1002/art.39193. PMID: 25989265). 
218. Eustace AD, McNaughton EF, King S, Kehoe O, Kungl A, Mattey D, Nobbs AH, Williams N, 
Middleton J. 2019. Soluble syndecan-3 binds chemokines, reduces leukocyte migration in vitro and 
ameliorates disease severity in models of rheumatoid arthritis. Arthritis Res Ther. 21:172. (doi: 
10.1186/s13075-019-1939-2). 
219. Patterson AM, Gardner L, Shaw J, David G, Loreau E, Aguilar L, Ashton BA, Middleton J. 
2005. Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium. 
Arthritis Rheum. 52:2331-42. (doi: 10.1002/art.21222).  
220.  Murphy-Ullrich JE. 2019. Thrombospondin 1 and its diverse roles as a regulator of 
extracellular matrix in fibrotic disease. J Histochem Cytochem. 67:683-699.( doi: 10.1369/0) 
221.  Conroy KP, Kitto LJ, Henderson NC. 2016. αv integrins: key regulators of tissue fibrosis. Cell 
Tissue Res. 365:511-9. (doi: 10.1007/s00441-016-2407-9).  
222.  Györfi AH, Matei AE, Distler JHW. 2018. Targeting TGF-β signaling for the treatment of 
fibrosis. Matrix Biol. 68-69:8-27. (doi: 10.1016/j.matbio.2017.12.016).  
223. Chen L, Klass C, Woods A. 2004. Syndecan-2 regulates transforming growth factor-beta 
signaling. J Biol Chem. 279:15715-8. doi: 10.1074/jbc.C300430200.  
224. Ruiz XD, Mlakar LR, Yamaguchi Y, Su Y, Larregina AT, Pilewski JM, Feghali-Bostwick CA. 
2012. Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-
expressed in fibrosis. PLoS One. 78:e43049. doi: 10.1371/journal.pone.0043049.  
225. Tsoyi K, Chu SG, Patino-Jaramillo NG, Wilder J, Villalba J, Doyle-Eisele M, McDonald J, Liu X, 
El-Chemaly S, Perrella MA, Rosas IO. 2017. Syndecan-2 attenuates radiation-induced pulmonary 
fibrosis and inhibits fibroblast activation by regulating PI3K/Akt/ROCK pathway via CD148. Am J 
Respir Cell Mol Biol. 58:208-215. (doi: 10.1165/rcmb.2017-0088OC). 
226. Whiteford JR, Xian X, Chaussade C, Vanhaesebroeck B, Nourshargh S, Couchman JR. 2011.  
Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148. Mol Biol Cell. 
22:3609-24. (doi: 10.1091/mbc.E11-02-0099).  
227. Jiang D, Liang J, Campanella GS, Guo R, Yu S, Xie T, Liu N, Jung Y, Homer R, Meltzer EB, Li Y, 
Tager AM, Goetinck PF, Luster AD, Noble PW. 2010. Inhibition of pulmonary fibrosis in mice by 
CXCL10 requires glycosaminoglycan binding and syndecan-4. J Clin Invest. 120:2049-57. (doi: 
10.1172/JCI38644).  
228. Scarpellini A, Huang L, Burhan I, Schroeder N, Funck M, Johnson TS, Verderio EA. 2014. 
Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against 
tubulointerstitial fibrosis. J Am Soc Nephrol. 25:1013-27. (doi: 10.1681/ASN.2013050563).  
229. Cagno V, Tseligka ED, Jones ST, Tapparel C. 2019. Heparan sulfate proteoglycans and viral 
attachment: true receptors or adaptation bias? Viruses. 11:596. (doi: 10.3390/v11070596).  
230. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg 
RD, Spear PG. 1999. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. 
Cell. 99:13-22. (doi: 10.1016/s0092-8674(00)80058-6).  
231. Akhtar J, Shukla D. 2009. Viral entry mechanisms: cellular and viral mediators of herpes 
simplex virus entry. FEBS J. 276:7228-36. (doi: 10.1111/j.1742-4658.2009.07402.x).  
232. Bacsa S, Karasneh G, Dosa S, Liu J, Valyi-Nagy T, Shukla D. 2011. Syndecan-1 and syndecan-
2 play key roles in herpes simplex virus type-1 infection. J Gen Virol. 92:733-43. (doi: 
10.1099/vir.0.027052-0).  
233. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. 1997. Dengue 
virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med. 
3:866-71. (doi: 10.1038/nm0897-866).  
234. Cruz-Oliveira C, Freire JM, Conceição TM, Higa LM, Castanho MA, Da Poian AT. 2015. 
Receptors and routes of dengue virus entry into the host cells. FEMS Microbiol Rev. 39:155-70. 
(doi: 10.1093/femsre/fuu004).  
235. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. 2003.  
Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J 
Virol. 77:13125-35. (doi: 10.1128/jvi.77.24.13125-13135.2003).  
236. Richards KF, Bienkowska-Haba M, Dasgupta J, Chen XS, Sapp M. 2013. Multiple heparan 
sulfate binding site engagements are required for the infectious entry of human papillomavirus 
type 16. J Virol. 87:11426-37. (doi: 10.1128/JVI.01721-13). 
237. Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M, Kast WM. 
2013. The evolving field of human papillomavirus receptor research: a review of binding and entry. 
J Virol. 87:6062-72. (doi: 10.1128/JVI.00330-13).  
238. Baba M, Snoeck R, Pauwels R, de Clercq E. 1988. Sulfated polysaccharides are potent and 
selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, 
vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother. 
32:1742-5. (doi: 10.1128/aac.32.11.1742).  
239. de Haan CA, Haijema BJ, Schellen P, Wichgers Schreur P, te Lintelo E, Vennema H, Rottier 
PJ. 2008. Cleavage of group 1 coronavirus spike proteins: how furin cleavage is traded off against 
heparan sulfate binding upon cell culture adaptation. J Virol. 82:6078-83. (doi: 10.1128/JVI.00074-
08).  
240. Kwon PS, Oh H, Kwon SJ, Jin W, Zhang F, Fraser K, Hong JJ, Linhardt RJ, Dordick JS. 2020. 
Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro. Cell Discov. 6:50. (doi: 
10.1038/s41421-020-00192-8).  
241. Tandon R, Sharp JS, Zhang F, Pomin VH, Ashpole NM, Mitra D, Jin W, Liu H, Sharma P, 
Linhardt RJ. 2020. Effective inhibition of SARS-CoV-2 entry by heparin and Enoxaparin derivatives. 
bioRxiv. 8:2020.06.08.140236. (doi: 10.1101/2020.06.08.140236).  
242. Liu L, Chopra P, Li X, Wolfert MA, Tompkins SM, Boons GJ. 2020. SARS-CoV-2 spike protein 
binds heparan sulfate in a length- and sequence-dependent manner. bioRxiv 
10:2020.05.10.087288. (doi: 10.1101/2020.05.10.087288). 
243. Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, Narayanan A, Majowicz 
SA, Kwong EM, McVicar RN et al. 2020.  SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate 
and ACE2. Cell. S0092-8674(20)31230-7. (doi: 10.1016/j.cell.2020.09.033).  
244. Daly JL, Simonetti B, Klein K, Chen KE, Williamson MK, Antón-Plágaro C, Shoemark DK, 
Simón-Gracia L, Bauer M, Hollandi R  et al. 2020. Neuropilin-1 is a host factor for SARS-CoV-2 
infection. Science.  20:eabd3072. (doi: 10.1126/science.abd3072). 
245. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, 
Kallio K, Kaya T, Anastasina M  et al. 2020. Neuropilin-1 facilitates SARS-CoV-2 cell entry and 
infectivity. Science 20:eabd2985. (doi: 10.1126/science.abd2985).  
246.  Saunders S, Jalkanen M, O'Farrell S, Bernfield M. 1989. Molecular cloning of syndecan, an 
integral membrane proteoglycan. J Cell Biol. 108:1547-56. doi: 10.1083/jcb.108.4.1547. 
247.  Sun C, Mahendravada A, Ballard B, Kale B, Ramos C, West J, Maguire T, McKay K, Lichtman 
E, Tuchman S et al. 2019. Safety and efficacy of targeting CD138 with a chimeric antigen receptor 




This work was supported by NHMRC (GNT1161439), ARC (DE190100174) and Monash Senior 
Postdoctoral Fellowship to SG. JW and SA gratefully acknowledge funding from the Macular 
Society and The Dunhill Medical Trust (grant# RPGF1906\173). The authors also acknowledge 
extensive assistance from Dr. Hinke Multhaupt (University of Copenhagen) in the preparation of 
the manuscript. We also acknowledge much valuable interaction with colleagues in the field and 




Figure 1.A. Schematic of the overall structure of the four mammalian syndecan core proteins and 
the composition of their heparan and chondroitin sulphate chains. Core protein-proximal regions 
of the heparan sulphate chains may be poorly sulphated or unsulphated and chains generally 
consist of highly sulphated domains interspersed with regions of low sulphation. At the interfaces 
between the two, there are regions of intermediate sulphation (see refs 33, 49). B. Organisation 
and amino acid sequences of the human syndecan cytoplasmic domains. Two regions (C1 and C2) 
highly conserved across all syndecans while the variable (V) regions are specific to each syndecan, 
yet may be highly conserved across species. 
Figure 2.  A) SDN-1 controls neuronal migration during C. elegans development. The image shows 
a selection of SDN-1 regulated neurons.  B) Schematic showing germline development in 
hermaphroditic C. elegans. SDN-1 is required for the correct positioning of the distal tip cells 
(DTC). Two DTCs appear post embryonically and migrate in opposite directions from somatic 
gonad primordium until L4 larval stage. DTCs acts as a niche for germline stem cells in C. elegans 
and promote proliferation of stem cells.   The hermaphrodite germline first completes the 
production of sperm at L4 stage before switching to oocytes in young adults. The sperm stored in 
spermatheca fertilizes the oocytes from which embryos develop.  
Figure 3. Leukocytes express a diverse range of syndecans (red) and glypicans (green). It is 
interesting to note that cells which are intimately associated with producing chemokines and 
cytokines such as macrophages and dendritic cells possess the most diverse portfolio of HSPGs. 
Leukocyte representations were generated with the aid of www.biorender.com. For references 
see 140-157. 
Figure 4. Syndecans have contrasting roles in angiogenesis. On the one hand they have been 
shown to facilitate the interaction between VEGF isoforms and their receptors e.g. (SDC1, SDC2 
and SDC4). However, sequences in the extracellular core proteins of syndecans also have 
antiangiogenic properties (SDC1, SDC2 and SDC3). These either act directly on integrins or via the 
action of tertiary receptors. For references see 39,40,42,122,198-210. 
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Related disease model phenotype in null mice 
SDC1 Inflammatory bowel 
disease 
Increased disease severity in Sdc1-/- mice in dextran 
sodium sulfate (DSS) model of inflammatory bowel 
disease. (37) 
SDC1  Bacterial infection Sdc1-/- mice are resistant to Pseudomonas aeruginosa 
infection. (38) 
SDC1  Ischemic injury Impaired arteriogenesis in Sdc1-/- mice in response to 
hindlimb ischemia. (39) 
SDC2 Wound healing EC specific Sdc2-/- animals exhibit impaired wound healing 
associated with impaired neovascularisation responses. 
(40) 
SDC3 Obesity Sdc3-/- mice are resistant to obesity when fed high fat 
diet. (9) 
SDC3 Rheumatoid Arthritis Sdc3-/- mice have improved outcomes in CXCL1 and 
antigen induced models of RA. (41) 
SDC4 Inflammatory bowel 
disease 
Increased disease severity in Sdc4-/- mice in dextran 
sodium sulfate (DSS) model of inflammatory bowel disease 
(42) 
SDC4 Wound healing Sdc4-/- mice have impaired dermal wound healing  (43) 
SDC4 Osteoarthritis and 
Rheumatoid arthritis 
Sdc4-/- mice are protected in models of osteoarthritis and 
RA. (44) 
SDC4 Pressure induced heart 
Failure 
Sdc4-/- mice exhibited reduced tissue repair responses in 
the heart following pressure overload. (45) 
SDC4 Lung fibrosis Sdc4-/- mice protected in the bleomycin-induced lung 
fibrosis model. (46) 
SDC4 Septic shock Worse outcomes are observed in mice subjected to 
endotoxin shock. (47) 
 
Table 1. Syndecans in Human Disease and Pathology. 
Selected examples of the use of syndecan null mice in disease models. All four syndecan deficient mouse 
strains develop normally, it is only when subjected to a challenge that phenotypes emerge. Cancer models 
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L1/L2 - DTCs are born post-embryonically
L2/L3 - DTCs migrate in opposite directions
L3 - DTCs continue to migrate
L4- DTC migration completed
Adult
Sperms
EmbryosOogenesis
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